var title_f12_50_13088="Stocking donner";
var content_f12_50_13088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Using a stocking donner to put on compression stockings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13088=[""].join("\n");
var outline_f12_50_13088=null;
var title_f12_50_13089="Gonococcal urethral swab";
var content_f12_50_13089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain of gonococcus in urethral discharge",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of purulent exudate from the male urethra (x1000) shows polymorphonuclear leukocytes containing numerous intracellular Gram negative diplococci. As expected, Neisseria gonorrhoeae grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13089=[""].join("\n");
var outline_f12_50_13089=null;
var title_f12_50_13090="Asbestosis histology A";
var content_f12_50_13090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestos-related small airway disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    H&amp;E-stained section showing junction of terminal (membranous) bronchiole with a respiratory bronchiole from a person with asbestosis who was an ex-smoker. The walls of the bronchioles are thickened by collagen and show mild smooth muscle hyperplasia. There is a mild chronic inflammatory cell infiltrate in the wall. These features are consistent with asbestos-related small airway disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13090=[""].join("\n");
var outline_f12_50_13090=null;
var title_f12_50_13091="Pseudomonas nail";
var content_f12_50_13091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Nail infection from Pseudomonas aeruginosa (green nail syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13091=[""].join("\n");
var outline_f12_50_13091=null;
var title_f12_50_13092="Doppler echo for LV pressure";
var content_f12_50_13092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular filling pressures in hypertrophic cardiomyopathy measured by tissue Doppler echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left ventricular filling pressures can be estimated using transmitral velocity (panel A), mitral annular velocity (panel B) and the flow propagation velocity (panel C) which is the slope of the linear component of the color border produced by the propagation of early filling peak velocity (E) into the left ventricle, past the mitral valve. In this patient the early diastolic peak filling velocity across the mitral valve (E) is about 100 cm/sec and lower than late diastolic peak filling velocity (panel A). The early diastolic peak filling velocity across the mitral annulus (Ea) is 6 cm/sec and is also lower than the late peak filling velocity (Aa). The ratio of E/Ea (16.7) correlates with the left ventricular filling pressure (Pre A) of 24 mmHg obtained at the time of cardiac catheterization (panel D). EDP indicates LVEDP; Pre-A, left ventricular filling pressure prior to atrial contraction.",
"    <div class=\"footnotes\">",
"     EDP: LVEDP; Pre-A: left ventricular filling pressure prior to atrial contraction.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Nagueh, MD, Lakkis, NM, Middleton, KJ, et al, Circulation 1999; 99:254.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13092=[""].join("\n");
var outline_f12_50_13092=null;
var title_f12_50_13093="Technical aspects of the signal-averaged electrocardiogram";
var content_f12_50_13093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Technical aspects of the signal-averaged electrocardiogram",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Sanjiv M Narayan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Michael E Cain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13093/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/50/13093/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signal-averaged electrocardiogram (SAECG) is a computerized technique for detecting subtle abnormalities in the surface electrocardiogram (ECG) that are not visible to the naked eye. The SAECG is derived by computing the arithmetic mean of multiple ECG complexes. This process increases the signal-to-noise ratio of cardiac potentials and enables the detection of much smaller (ie, microvolt-level) signals than would otherwise be discernible from the surface ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/1\">",
"     1",
"    </a>",
"    ]. Signals from the His bundle as well as subtle abnormalities of atrial or ventricular complexes, anomalies not visualized on a surface ECG, are detectable using the SAECG [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SAECG has most often been used to identify low-amplitude signals at the end of the QRS complex, referred to as \"ventricular late potentials\". These late potentials represent delayed ventricular activation, which may reflect the presence of myocardial scar tissue and identify patients at increased risk for reentrant ventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/4\">",
"     4",
"    </a>",
"    ]. The SAECG is particularly useful in understanding the arrhythmic substrate and stratifying risk for ventricular tachyarrhythmias in patients with cardiomyopathies of various etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the SAECG can also be useful in evaluating the risk for atrial arrhythmias. Studies suggest that a prolonged SAECG P-wave, equivalent to \"atrial late potentials\", may identify patients at risk for atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Finally, the SAECG can also improve the resolution of atrial from ventricular activation for improved ECG diagnosis of supraventricular tachyarrhythmias.",
"   </p>",
"   <p>",
"    The technical aspects of the SAECG and the characteristics of late potentials will be reviewed here. The clinical use of the SAECG is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27544?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrical signals of interest that reflect delayed conduction through ventricular or atrial scar are minute compared with the size of the QRS complex or P-wave seen on a surface ECG. Although simple amplification of the ECG may reveal these signals, it also amplifies ambient noise, which typically masks the useful low-amplitude signals. Conversely, averaging multiple QRS complexes (or P-waves) \"reinforces\" the consistent ventricular or atrial components while diminishing the inconsistent noise components, thus improving the signal-to-noise ratio. The ECG can be averaged over time (\"temporal averaging\") or spatially, and this process has been further enhanced by digital filtering and spectral analysis.",
"   </p>",
"   <p>",
"    The ideal number and configuration of ECG leads used to record the signal-averaged ECG is unclear, but the most commonly used lead set uses three bipolar leads in a standard X, Y, and Z (orthogonal) arrangement (",
"    <a class=\"graphic graphic_figure graphicRef75403 \" href=\"UTD.htm?1/8/1153\">",
"     figure 1",
"    </a>",
"    ). In most cases, the averaging of 200 to 400 QRS complexes with the same morphology, over approximately three to seven minutes, are sufficient to record an adequate SAECG.",
"   </p>",
"   <p>",
"    Signal filtering further augments signal detection of the SAECG and minimizes random noise that is not synchronized to the QRS complex. As an example, filters facilitate easy recognition of QRS onset and offset. They may also help with the detection of low-amplitude, high-frequency signals, such as late potentials or atrial activity, during the otherwise low-frequency or isoelectric ST segment.",
"   </p>",
"   <p>",
"    The most commonly used filters are bi-directional filters. In this setup, the high-pass component removes low-frequency activity, such as that due to baseline drift of the ECG signal and low-frequency components of the ST segment and T waves. The low-pass components remove high-frequency noise, such as pectoral muscle components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Temporal signal averaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly applied SAECG method, temporal signal averaging, averages a number of QRS complexes over time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/7\">",
"     7",
"    </a>",
"    ]. Beats are detected by computer algorithms, based on voltage thresholds or other criteria, then aligned by a constant feature of the signal, the \"fiducial\" (",
"    <a class=\"graphic graphic_figure graphicRef75403 \" href=\"UTD.htm?1/8/1153\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef67428 \" href=\"UTD.htm?27/32/28175\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/8\">",
"     8",
"    </a>",
"    ]. Once beats have been aligned, their arithmetic mean is taken. This process diminishes random noise that is not synchronized to the QRS complex.",
"   </p>",
"   <p>",
"    Since averaging is performed until a \"noise floor\" is reached, the lower the initial baseline noise level, the fewer the number of beats required to generate the SAECG, and the better the resultant signal. However, in order to obtain a reliable averaged signal, only QRS complexes of similar beat-to-beat morphology should be analyzed. Thus, premature ventricular beats, aberrantly conducted beats, or grossly \"noisy\" beats are excluded from the analysis. An automated algorithm typically generates an \"acceptable\" template from the first few QRS complexes, then compares each successive beat for \"closeness of fit\" with the template before incorporating the beat into the average [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Temporal signal averaging has some inherent limitations. First, this technique can only enhance signals that occur in a fixed relationship to the fiducial point. Thus, if there is significant variability in the morphology of late potentials from beat to beat, they may actually be considered to be \"noise\" and diminished by averaging. Second, ventricular late potentials can only be detected from the body surface when the fragmented activity outlasts the normal ventricular activation. Thus, in patients with bundle branch block, late potentials may be obscured by the delayed activation of normal ventricular myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spatial signal averaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG spatial averaging involves the summation and averaging of electrical potentials simultaneously recorded from multiple pairs of closely spaced electrodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/10\">",
"     10",
"    </a>",
"    ]. This process allows a real-time, beat-by-beat analysis of individual QRS complexes, but requires electrical shielding of the patient and equipment. The advantage of this technique over temporal signal averaging is that it allows assessment of irregular rhythms with changing conduction.",
"   </p>",
"   <p>",
"    Although often considered distinct from the SAECG, spatial averaging is the basis of laplacian filtering embodied in electrodes used to record beat-to-beat dynamics of T-wave alternans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/11\">",
"     11",
"    </a>",
"    ]. The principle of spatial averaging is also the basis for high-resolution body surface potential mapping that may detect the risk for sudden cardiac arrest or other arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Finally, spatial averaging also allows dynamic changes to be evaluated after drug therapy, after ectopic beats, or after the onset of ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Spectral analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectral analysis considers the QRS complex (or P-wave) to be composed of multiple simple waveforms, typically sinusoids. Spectral analysis thus decomposes the QRS complex or P-wave into these constituent signals, represented by component frequencies and corresponding phase and amplitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Spectral decomposition is typically performed using Fourier analysis, although methods such as wavelet transform have also been successfully applied [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional approach is the combination of time and frequency-domain techniques (spectrotemporal analysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/16\">",
"     16",
"    </a>",
"    ]. This procedure presents the Fourier transform of multiple segments of the ECG signal, shifted in time as a three-dimensional plot of the magnitude of individual signal frequencies against time. Thus, this technique may overcome the disadvantages of temporal signal averaging by allowing identification of fractionated activity occurring within the QRS complex (eg, in patients with an intraventricular conduction delay or a bundle branch block).",
"   </p>",
"   <p>",
"    Combined time and frequency-domain analysis has been used to improve the ability of the SAECG to predict arrhythmic events after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/17\">",
"     17",
"    </a>",
"    ]. The response to antiarrhythmic drugs may also be determined from specific changes in the frequency content of the QRS complex [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DEFINITION OF LATE POTENTIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late potentials are defined by three criteria (",
"    <a class=\"graphic graphic_waveform graphicRef67428 \" href=\"UTD.htm?27/32/28175\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total filtered QRS duration",
"     </li>",
"     <li>",
"      Voltage in the terminal portion of the QRS (usually the last 40 msec)",
"     </li>",
"     <li>",
"      Duration of the terminal QRS that is below a particular amplitude (usually 40 mcV), called the late potential duration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This definition of late potentials is empiric, yet has become validated over time by clinical observations. Notably, values for each parameter depend upon the type and frequency response of the filters used in the signal-averaging system. The most commonly used algorithms employ a 40 or 25-Hz high-pass filter. Using the 40-Hz filter, a Task Force Committee of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology suggested the following definition of late potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13093/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Filtered QRS duration &gt;114 msec",
"     </li>",
"     <li>",
"      Terminal (last 40 msec) QRS root mean square voltage &lt;20 mcV",
"     </li>",
"     <li>",
"      Low amplitude (&lt;40mcV) late potential duration &gt;38 msec",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite this attempt at standardization, authors have used variations of these criteria, and definitions for spectral (frequency domain) analysis of late potentials have not been standardized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5634240\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signal averaged electrocardiogram (SAECG) is useful for detecting subtle abnormalities in the surface electrocardiogram (ECG) that are not visible to the naked eye. One example of such an abnormality is the \"ventricular late potential\", a low-amplitude signal near the end of the QRS complex which can be used to stratify risk for ventricular tachyarrhythmias in patients with cardiomyopathies of various etiologies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"       \"Reentry and the development of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The SAECG can be acquired by one of three methods (temporal signal averaging, spatial signal averaging, or spectral analysis), all with inherent benefits and limitations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Temporal signal averaging, the most common method for obtaining the SAECG, averages a number of QRS complexes over time. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Temporal signal averaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spatial signal averaging analyzes electrical potentials simultaneously recorded from multiple pairs of closely spaced electrodes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Spatial signal averaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spectral analysis considers the QRS complex (or P-wave) to be composed of multiple simple waveforms, typically sinusoids. Spectral analysis thus decomposes the QRS complex (or P-wave) into these constituent signals for analysis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spectral analysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following time analyses, derived from temporal signal averaging, are the most frequently used criteria to define an abnormal SAECG: (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Definition of late potentials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Filtered QRS duration &gt;114 msec",
"     </li>",
"     <li>",
"      Terminal (last 40 msec) QRS root mean square voltage &lt;20 mcV",
"     </li>",
"     <li>",
"      Low amplitude (&lt;40mcV) late potential duration &gt;38 msec",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/1\">",
"      Berbari EJ, Scherlag BJ, Hope RR, Lazzara R. Recording from the body surface of arrhythmogenic ventricular activity during the S-T segment. Am J Cardiol 1978; 41:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/2\">",
"      Berbari EJ, Lazzara R, Samet P, Scherlag BJ. Noninvasive technique for detection of electrical activity during the P-R segment. Circulation 1973; 48:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/3\">",
"      Cain ME, Anderson JL, Arnsdorf MF, et, al. Signal-averaged electrocardiography. ACC Expert Consensus Document. J Am Coll Cardiol 1996; 27:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/4\">",
"      Hood MA, Pogwizd SM, Peirick J, Cain ME. Contribution of myocardium responsible for ventricular tachycardia to abnormalities detected by analysis of signal-averaged ECGs. Circulation 1992; 86:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/5\">",
"      Ehlert FA, Steinberg JS. The P wave signal-averaged ECG. J Electrocardiol 1995; 28 Suppl:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/6\">",
"      Abe Y, Fukunami M, Yamada T, et al. Prediction of transition to chronic atrial fibrillation in patients with paroxysmal atrial fibrillation by signal-averaged electrocardiography: a prospective study. Circulation 1997; 96:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/7\">",
"      Simson MB, Untereker WJ, Spielman SR, et al. Relation between late potentials on the body surface and directly recorded fragmented electrograms in patients with ventricular tachycardia. Am J Cardiol 1983; 51:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/8\">",
"      Narayan SM, Smith JM. Spectral analysis of periodic fluctuations in electrocardiographic repolarization. IEEE Trans Biomed Eng 1999; 46:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/9\">",
"      Steinberg JS, Bigger JT Jr. Importance of the endpoint of noise reduction in analysis of the signal-averaged electrocardiogram. Am J Cardiol 1989; 63:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/10\">",
"      El-Sherif N, Mehra R, Gomes JA, Kelen G. Appraisal of a Low Noise Electrocardiogram. J Am Coll Cardiol 1983; 1:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/11\">",
"      He B, Cohen RJ. Body surface Laplacian electrocardiographic mapping--a review. Crit Rev Biomed Eng 1995; 23:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/12\">",
"      Kavesh NG, Cain ME, Ambos HD, Arthur RM. Enhanced detection of distinguishing features in signal-averaged electrocardiograms from patients with ventricular tachycardia by combined spatial and spectral analyses of entire cardiac cycle. Circulation 1994; 90:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/13\">",
"      SippensGroenewegen A, Lesh MD, Roithinger FX, et al. Body surface mapping of counterclockwise and clockwise typical atrial flutter: a comparative analysis with endocardial activation sequence mapping. J Am Coll Cardiol 2000; 35:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/14\">",
"      Cain ME, Ambos HD, Witkowski FX, Sobel BE. Fast-Fourier transform analysis of signal-averaged electrocardiograms for identification of patients prone to sustained ventricular tachycardia. Circulation 1984; 69:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/15\">",
"      Machac J, Weiss A, Winters SL, et al. A comparative study of frequency domain and time domain analysis of signal-averaged electrocardiograms in patients with ventricular tachycardia. J Am Coll Cardiol 1988; 11:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/16\">",
"      Haberl R, Jilge G, Pulter R, Steinbeck G. Spectral mapping of the electrocardiogram with Fourier transform for identification of patients with sustained ventricular tachycardia and coronary artery disease. Eur Heart J 1989; 10:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/17\">",
"      V&aacute;zquez R, Caref EB, Torres F, et al. Improved diagnostic value of combined time and frequency domain analysis of the signal-averaged electrocardiogram after myocardial infarction. J Am Coll Cardiol 1999; 33:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/18\">",
"      Wolzt M, Schmetterer L, Kastner J, et al. Short-term drug effects on the signal-averaged electrocardiogram in healthy men: assessment of intra- and interindividual variability of spectral temporal mapping and time-domain analysis. J Pharmacol Exp Ther 1995; 275:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/19\">",
"      Simson MB. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 1981; 64:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13093/abstract/20\">",
"      Breithardt G, Cain ME, el-Sherif N, et al. Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography: a statement by a task force committee of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology. J Am Coll Cardiol 1991; 17:999.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 959 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-422ACB6E1F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13093=[""].join("\n");
var outline_f12_50_13093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5634240\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Temporal signal averaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spatial signal averaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Spectral analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DEFINITION OF LATE POTENTIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5634240\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/959\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/959|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/8/1153\" title=\"figure 1\">",
"      QRS alignment methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/959|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/32/28175\" title=\"waveform 1\">",
"      Computing SAECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27544?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_50_13094="Physiology of leptin";
var content_f12_50_13094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of leptin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13094/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13094/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13094/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13094/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13094/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13094/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/50/13094/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin is a product of the OB gene, which is expressed primarily in adipocytes. Leptin acts on leptin receptors, which are widely distributed and account for its pleiotropic effects on energy homeostasis, neuroendocrine function, and immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/1\">",
"     1",
"    </a>",
"    ]. Leptin was discovered as a result of studies of",
"    <span class=\"nowrap\">",
"     ob/ob",
"    </span>",
"    mice, a strain of hyperphagic obese mice that lost weight when their circulation was attached to normal mice (parabiosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/2\">",
"     2",
"    </a>",
"    ]. These mice, which grew poorly and had infertility due to gonadal hypofunction, were used for cloning studies that resulted in the isolation of leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/3\">",
"     3",
"    </a>",
"    ]. Humans with leptin deficiency were soon identified. Administration of leptin to leptin deficient humans or animals resulted in a marked decrease in food intake, weight loss, and improved growth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/4\">",
"     4",
"    </a>",
"    ]. Other obese mice, diabetic",
"    <span class=\"nowrap\">",
"     (db/db)",
"    </span>",
"    mouse and fatty (Zucker) rat, and humans have genetic defects in the leptin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These findings demonstrated that a molecular defect could produce obesity in animals and human beings and gave hope that human obesity might result from a defect in this gene (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link\">",
"     \"Pathogenesis of obesity\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTION OF LEPTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans, the leptin gene is located on chromosome 7q32 and consists of three exons and two introns that span 20 kilobases (kb) of DNA. The mouse and human ob genes have 84 percent homology. The gene codes for a secreted protein of 167 amino acids. Leptin is a member of the cytokine family, and its receptor is a member of the gp130 group of cytokine receptors. There are at least five forms of the leptin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/5\">",
"     5",
"    </a>",
"    ]. The most widely distributed is the short form of the receptor, which is present in most tissues and may serve to transport leptin into the brain. The long form of the receptor is located in areas where leptin is thought to act, including hypothalamic nuclei. There is also a circulating form of the leptin receptor that binds leptin and may modulate its action [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signaling system on the intracellular portion of the leptin receptor belongs to the janus kinase signal transduction and translation system (JAK STAT). It is the Stat-3 form of the STAT system that is thought to carry out the intracellular signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/8\">",
"     8",
"    </a>",
"    ]. The suppressors of cytokine signaling (SOCS3) are",
"    <strong>",
"    </strong>",
"    a counter-regulatory system that inhibits leptin. Protein tyrosine phosphatase 1B is also an inhibitor of leptin receptor signaling, and its deficiency protects from leptin resistance in fat fed animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4804427\">",
"    <span class=\"h1\">",
"     BIOLOGY OF LEPTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin is produced primarily in fat cells, and also in the placenta and probably in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/4\">",
"     4",
"    </a>",
"    ]. Large fat cells produce more leptin than small ones and serum leptin concentrations are highly correlated with body fat content in newborn infants, children, and adults. Leptin mRNA and secretion by adipocytes declines rapidly during starvation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/9\">",
"     9",
"    </a>",
"    ]. These processes are stimulated by insulin, glucocorticoids and tumor necrosis factor-alpha, another product of adipocytes. These observations suggest that leptin signals the brain about the quantity of stored fat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4804434\">",
"    <span class=\"h2\">",
"     Regulation of feeding by leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food intake is reduced by systemic leptin administration in normal-weight experimental animals, but the response decreases as the animals become obese. However, when leptin is injected into the ventricular system of the brain of obese animals, they remain responsive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/9\">",
"     9",
"    </a>",
"    ]. Transport of leptin across the blood-brain barrier may control the entrance of leptin into the brain and modulate its action on food intake.",
"   </p>",
"   <p>",
"    Leptin decreases food intake in several ways. It decreases the content of neuropeptide Y (NPY) mRNA and increases the content of proopiomelanocortin (POMC) mRNA in the arcuate nucleus of the hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/10\">",
"     10",
"    </a>",
"    ]. NPY is one of the most potent stimulators of food intake [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/10\">",
"     10",
"    </a>",
"    ]. Alpha-melanocyte-stimulating hormone (alpha-MSH), produced by cleavage of POMC, inhibits food intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leptin production in humans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body mass index (BMI) and body fat are strongly correlated with leptin production [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/4\">",
"     4",
"    </a>",
"    ]. Under conditions of regular food intake, leptin concentrations reflect the proportion of adipose tissue. Overeating increases serum leptin concentrations by nearly 40 percent within 12 hours, long before any changes in body fat stores. Conversely, in both normal-weight and obese subjects, fasting reduces serum leptin concentrations by 60 to 70 percent in 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/11\">",
"     11",
"    </a>",
"    ]. Features of leptin production in humans, in addition to the correlation with body fat content, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women have higher serum leptin concentrations than men, and pregnant women have higher concentrations than nonpregnant women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The placenta and breast milk are sources of leptin [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum leptin concentrations increase during childhood, with the highest concentrations in children who gain the most weight; higher serum leptin concentrations are associated with an earlier onset of puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethnicity does not influence serum leptin concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The concentrations are similar in normal subjects and patients with type 2 diabetes mellitus of the same weight, but hyperinsulinemia increases glucose utilization and the production of leptin in adipocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a diurnal rhythm of serum leptin concentrations, the values being 20 to 40 percent higher in the middle of the night as compared with daytime [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/15\">",
"       15",
"      </a>",
"      ]. The peak shifts in parallel with shifts in the timing of meals.",
"     </li>",
"     <li>",
"      In human beings, plasma leptin is related to blood pressure levels in both normotensive [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/16\">",
"       16",
"      </a>",
"      ] and hypertensive subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791180\">",
"    <span class=\"h2\">",
"     Prothrombotic effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin also may have a prothrombotic effect. Leptin-deficient mice form an occlusive thrombus more slowly than wild-type mice, a change reversed by leptin replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/19\">",
"     19",
"    </a>",
"    ]. This effect appears to be mediated through the platelet leptin receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791187\">",
"    <span class=\"h2\">",
"     Bone formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effect of leptin on bone metabolism are conflicting. In obese mouse models deficient in leptin",
"    <span class=\"nowrap\">",
"     (ob/ob)",
"    </span>",
"    or its receptor",
"    <span class=\"nowrap\">",
"     (db/db),",
"    </span>",
"    bone formation and bone mass have been reported to be both increased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/20\">",
"     20",
"    </a>",
"    ], decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/21\">",
"     21",
"    </a>",
"    ], or variable depending upon the bone site [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/22\">",
"     22",
"    </a>",
"    ]. It appears that leptin's effects on energy balance and bone occur at the level of the hypothalamus, although the pathways appear to be distinct [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data in the human are also inconclusive, as observational studies have reported both a positive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/23-25\">",
"     23-25",
"    </a>",
"    ] and negative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/26-29\">",
"     26-29",
"    </a>",
"    ] association between serum leptin concentrations and bone density. However, in a study of exogenous leptin administration in women with hypothalamic amenorrhea (who are leptin deficient), an increase in bone mineral content of the lumbar spine was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791194\">",
"    <span class=\"h2\">",
"     Immune Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin links nutritional status with immune function. The decrease in leptin concentration during food deprivation results in impaired immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/1\">",
"     1",
"    </a>",
"    ]. Leptin deficient individuals have a decrease in CD4 cells and reduced T-cell production [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/31\">",
"     31",
"    </a>",
"    ] that is consistent with their higher rates of childhood infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/32\">",
"     32",
"    </a>",
"    ]. Leptin replacement leads to a switch from secretion of predominantly Th2 cytokines to Th1 cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary immune deficiency due to miscellaneous causes\", section on 'Malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791048\">",
"    <span class=\"h1\">",
"     LEPTIN AND DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Leptin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital leptin deficiency due to a mutation in the leptin gene produces massive obesity, similar to that seen in rodent models that lack leptin or leptin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Early-onset obesity and profound hyperphagia are characteristic of these individuals, as are hyperinsulinemia and advanced bone age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/31\">",
"     31",
"    </a>",
"    ]. Hypogonadotropic hypogonadism occurs in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/32\">",
"     32",
"    </a>",
"    ]. Leptin deficiency also reduces TSH pulsatility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/15\">",
"     15",
"    </a>",
"    ]. Serum leptin levels were significantly lower in heterozygous members of these families than would be expected from their percent body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/34\">",
"     34",
"    </a>",
"    ]. However, these heterozygotes had normal thyroid function, appropriate gonadotropin levels and normal secondary sexual characteristics, including menstrual cycles.",
"   </p>",
"   <p>",
"    Food intake decreases dramatically when treated with exogenous leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/31,35\">",
"     31,35",
"    </a>",
"    ]. Pubertal development was seen in one child, and serum concentrations of free thyroxine and TSH increased into the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/31\">",
"     31",
"    </a>",
"    ]. Resolution of type 2 diabetes and hypogonadism have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/35\">",
"     35",
"    </a>",
"    ]. Several mechanisms appear to be involved in the reduction in food intake with leptin therapy, including a decrease in hunger ratings in the fasted state, enhanced perception of satiety after a meal, and a diminished perception of food reward [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Leptin receptor deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human obesity resulting from a mutation in the leptin receptor (LEPR) has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one report, 8 of 300 subjects (3 percent) with severe, early-onset obesity had nonsense or missense LEPR mutations (six probands were from consanguineous families) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to severe obesity and hyperphagia, other characteristics of affected patients included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alterations in immune function (decrease in the absolute CD4+ T-cell count with compensatory increase in the CD19+ B-cell count) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normal linear growth, but reduced adult height as adults (due to lack of pubertal growth spurt).",
"     </li>",
"     <li>",
"      Delayed puberty due to hypogonadotropic hypogonadism.",
"     </li>",
"     <li>",
"      Increased serum leptin concentrations (consistent with their elevated fat mass, but not disproportionately increased, suggesting that serum leptin levels are not a useful marker for LEPR deficiency).",
"     </li>",
"     <li>",
"      Less severe clinical features when compared with patients with congenital leptin deficiency (less hyperphagia, lower BMI, and lower percentage body fat).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10202886\">",
"    <span class=\"h1\">",
"     TREATMENT WITH LEPTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further studies are required to understand the role of leptin in human physiology and its potential therapeutic role [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most obese people are not leptin deficient, and serum leptin concentrations are directly related to their amount of body fat. In several surveys of obese subjects, no mutations in the leptin gene were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/9\">",
"     9",
"    </a>",
"    ]. Given the high serum leptin concentrations and apparent leptin resistance in obese subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/9\">",
"     9",
"    </a>",
"    ], little response to exogenous leptin might be expected. However, in a study of the effect of recombinant leptin (0.01, 0.03, 0.1, or 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or placebo in normal-weight subjects for four weeks and obese subjects for 24 weeks, there was a very modest dose-dependent decrease in weight in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H39#H39\">",
"     \"Drug therapy of obesity\", section on 'Leptin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animals fed a high fat diet, treatment with amylin can restore leptin responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/38\">",
"     38",
"    </a>",
"    ]. This concept has been applied to a clinical trial showing that treatment with the combination of leptin and amylin led to significantly greater weight loss than treatment with amylin or leptin alone (&minus;12.7, -8.4, and -8.2 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After weight loss, leptin administration prevents the decline in metabolic rate and circulating concentrations of thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13094/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypothalamic amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hypothalamic amenorrhea (due to weight loss, excessive exercise, or an eating disorder) have lower serum concentrations of leptin, a protein that probably contributes to their low gonadotropin secretion as compared with similar-weight women who have normal menstrual cycles. Leptin administration for the relative leptin deficiency in women with functional hypothalamic amenorrhea may improve function of the reproductive axis (increased serum LH concentrations and pulsatility) as well as the thyroid and growth hormone axes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link&amp;anchor=H172207980#H172207980\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Role of leptin deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link&amp;anchor=H21437295#H21437295\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Leptin administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin-replacement therapy is effective in patients with lipodystrophy and leptin deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link&amp;anchor=H32#H32\">",
"     \"Lipodystrophic syndromes\", section on 'Leptin replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10202720\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leptin is a hormone secreted by adipocytes. It is involved in the regulation of food intake and energy homeostasis and links nutritional status with neuroendocrine and immune functions. (See",
"      <a class=\"local\" href=\"#H4804427\">",
"       'Biology of leptin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leptin administration in patients with congenital or acquired leptin deficiency (eg, patients with lipoatrophy) is effective in reversing the neuroendocrine, energy homeostasis, or metabolic abnormalities associated with the deficiency, whereas leptin is ineffective in obese patients with leptin excess (leptin resistance). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Leptin deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with hypothalamic amenorrhea (a state of relative leptin deficiency), administration of leptin improves the hypothalamic-associated abnormalities of the reproductive, thyroid, and growth hormone axes, and results in resumption of menses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link&amp;anchor=H21437295#H21437295\">",
"       \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Leptin administration'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/1\">",
"      Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med 2012; 33:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/2\">",
"      Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 1973; 9:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/3\">",
"      Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/4\">",
"      Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/5\">",
"      Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/6\">",
"      Cl&eacute;ment K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/7\">",
"      Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007; 356:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/8\">",
"      Lavens D, Piessevaux J, Tavernier J. Review: Negative regulation of leptin receptor signalling. Eur Cytokine Netw 2006; 17:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/9\">",
"      Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011; 121:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/10\">",
"      Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007; 583:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/11\">",
"      Weigle DS, Duell PB, Connor WE, et al. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J Clin Endocrinol Metab 1997; 82:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/12\">",
"      Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/13\">",
"      Lyle RE, Kincaid SC, Bryant JC, et al. Human milk contains detectable levels of immunoreactive leptin. Adv Exp Med Biol 2001; 501:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/14\">",
"      Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med (Maywood) 2001; 226:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/15\">",
"      Mantzoros CS, Ozata M, Negrao AB, et al. Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans. J Clin Endocrinol Metab 2001; 86:3284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/16\">",
"      Schorr U, Blaschke K, Turan S, et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998; 16:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/17\">",
"      Hirose H, Saito I, Tsujioka M, et al. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. J Hypertens 1998; 16:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/18\">",
"      Agata J, Masuda A, Takada M, et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/19\">",
"      Bodary PF, Westrick RJ, Wickenheiser KJ, et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/20\">",
"      Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/21\">",
"      Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000; 92:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/22\">",
"      Hamrick MW, Pennington C, Newton D, et al. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 2004; 34:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/23\">",
"      Schett G, Kiechl S, Bonora E, et al. Serum leptin level and the risk of nontraumatic fracture. Am J Med 2004; 117:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/24\">",
"      Thomas T, Burguera B, Melton LJ 3rd, et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/25\">",
"      Blain H, Vuillemin A, Guillemin F, et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2002; 87:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/26\">",
"      Sato M, Takeda N, Sarui H, et al. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab 2001; 86:5273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/27\">",
"      Ruhl CE, Everhart JE. Relationship of serum leptin concentration with bone mineral density in the United States population. J Bone Miner Res 2002; 17:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/28\">",
"      Blum M, Harris SS, Must A, et al. Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int 2003; 73:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/29\">",
"      Lorentzon M, Landin K, Mellstr&ouml;m D, Ohlsson C. Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 2006; 21:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/30\">",
"      Sienkiewicz E, Magkos F, Aronis KN, et al. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism 2011; 60:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/31\">",
"      Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/32\">",
"      Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84:3686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/33\">",
"      Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301:E567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/34\">",
"      Farooqi IS, Keogh JM, Kamath S, et al. Partial leptin deficiency and human adiposity. Nature 2001; 414:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/35\">",
"      Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/36\">",
"      Farooqi IS, Bullmore E, Keogh J, et al. Leptin regulates striatal regions and human eating behavior. Science 2007; 317:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/37\">",
"      Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/38\">",
"      Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008; 105:7257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/39\">",
"      Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13094/abstract/40\">",
"      Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115:3579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5373 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13094=[""].join("\n");
var outline_f12_50_13094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10202720\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTION OF LEPTIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4804427\">",
"      BIOLOGY OF LEPTIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4804434\">",
"      Regulation of feeding by leptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leptin production in humans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791180\">",
"      Prothrombotic effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791187\">",
"      Bone formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791194\">",
"      Immune Function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H791048\">",
"      LEPTIN AND DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Leptin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Leptin receptor deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10202886\">",
"      TREATMENT WITH LEPTIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypothalamic amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10202720\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_50_13095="Third degree or complete AV block with narrow QRS escape";
var content_f12_50_13095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1099px;\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Third degree (complete) atrioventricular block with narrow QRS escape rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 101px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The P waves are completely dissociated from the QRS complexes. The QRS complexes are narrow, indicating a junctional escape rhythm. The atrial and ventricular rates are stable; the former is faster than the latter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13095=[""].join("\n");
var outline_f12_50_13095=null;
var title_f12_50_13096="Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter";
var content_f12_50_13096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13096/contributors\">",
"     Donald O Castell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13096/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13096/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/50/13096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical relevance of esophageal motility abnormalities such as diffuse esophageal spasm (DES) and nutcracker esophagus is best understood when working from a classification system for these abnormalities.",
"   </p>",
"   <p>",
"    An esophageal motility disorder is defined as motility that differs significantly from accepted normal variations. Classifications of esophageal motility abnormalities are based upon motility findings that exceed two standard deviations from those found in a large group of normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable controversy concerning the clinical significance of abnormal esophageal motility patterns. The most important questions are whether they represent actual disorders or are only manometric abnormalities and whether they cause or explain the patient's symptoms. With the exceptions of achalasia and scleroderma, no specific pathology or pathophysiology has been described for any of these dysmotility patterns, including the more generally accepted \"disorder\" of DES.",
"   </p>",
"   <p>",
"    This topic review will attempt to characterize the relevant information on these motility abnormalities without the implication that they are actual disease entities, excluding the one true motility disorder, achalasia. Achalasia and chest pain of esophageal origin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ESOPHAGEAL MOTILITY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal motility abnormalities are generally classified into those that are an isolated phenomenon (primary) (",
"    <a class=\"graphic graphic_table graphicRef64858 \" href=\"UTD.htm?34/52/35660\">",
"     table 1",
"    </a>",
"    ) and those associated with generalized disease (secondary) (",
"    <a class=\"graphic graphic_table graphicRef75807 \" href=\"UTD.htm?24/17/24859\">",
"     table 2",
"    </a>",
"    ). Within each of these major categories, the motility abnormalities can usually be subcategorized into hypercontracting, hypocontracting, and discoordinated motility.",
"   </p>",
"   <p>",
"    There are different modalities for assessing esophageal motility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal motility abnormalities are usually defined through testing with stationary manometry performed during a series of 10 or more 5 mL liquid swallows under standardized conditions that permit comparison with the data obtained from normal volunteers. Usually sensors are spaced at 5 cm intervals (conventional manometry [CM]).",
"     </li>",
"     <li>",
"      Motility abnormalities based upon ambulatory monitoring of esophageal pressure are less clearly defined and need to be better categorized.",
"     </li>",
"     <li>",
"      High-resolution esophageal pressure topography (HREPT) is based upon high-resolution manometry (HRM) in which pressure sensors are closely spaced to obtain detailed manometric information [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/2\">",
"       2",
"      </a>",
"      ]. It offers technical advantages over conventional manometry because it monitors pressure in the esophagus, coupled with sophisticated algorithms displaying the manometric data (pressure topography plotting), and provides enhanced detail in the description of esophageal spasm, nutcracker esophagus, and the morphology of the esophageal gastric junction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/3\">",
"       3",
"      </a>",
"      ]. A classification system, the \"Chicago Classification,\" has been developed to categorize esophageal motility disorders using HREPT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/4\">",
"       4",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_table graphicRef59779 \" href=\"UTD.htm?14/23/14717\">",
"       table 3",
"      </a>",
"      ). Findings on HREPT correlate with findings on CM while providing additional information (",
"      <a class=\"graphic graphic_table graphicRef81969 \" href=\"UTD.htm?11/8/11404\">",
"       table 4",
"      </a>",
"      ). While HREPT provides more detailed information about esophageal function, its role in improving our ability to diagnose and treat patients more effectively remains to be determined.",
"     </li>",
"     <li>",
"      Esophageal multichannel intraluminal impedance testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"       \"Esophageal multichannel intraluminal impedance testing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three types of dysmotility that will be discussed below are characterized by the following findings during standardized motility testing (",
"    <a class=\"graphic graphic_table graphicRef64858 \" href=\"UTD.htm?34/52/35660\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse (or distal) esophageal spasm &ndash; 20 percent or more simultaneous contractions (with amplitude &gt;30 mmHg).",
"     </li>",
"     <li>",
"      Nutcracker esophagus &ndash; Average distal esophageal peristaltic pressures exceeding 220 mmHg during 10 or more 5 mL liquid swallows. In the past, nutcracker esophagus was defined by peristaltic pressures exceeding 180 mmHg, but that value is no longer used in an attempt to improve diagnostic specificity.",
"     </li>",
"     <li>",
"      Hypertensive lower esophageal sphincter &ndash; Resting lower esophageal sphincter pressure above 45 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These manometric findings are not mutually exclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMS OF ESOPHAGEAL MOTILITY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal esophageal function that is symptomatic is usually manifested by heartburn, regurgitation, dysphagia, or chest pain. As the primary manifestation of gastroesophageal reflux, heartburn is the easiest to diagnose and treat and is not likely to be a symptom of a primary motility disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, dysphagia and chest pain, sometimes occurring in the same patient, are clinical presentations that raise suspicion of a possible defect in esophageal motility. This observation is particularly true after coronary artery disease has been excluded in the patient with chest pain. Patients presenting with dysphagia should have an upper endoscopy and, if concern remains for an obstruction following a negative endoscopy, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    x-ray to exclude an obstructive abnormality before esophageal dysmotility is considered.",
"   </p>",
"   <p>",
"    The relationship between the esophageal dysmotility and the patient's symptoms may be uncertain. The true test of a clinically important abnormal motility pattern is related to its specific association with the patient's symptom, and a symptomatic response from therapy intended to alter the dysmotility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFUSE (OR DISTAL) ESOPHAGEAL SPASM",
"    </span>",
"    &nbsp;&mdash;&nbsp;While unexplained chest pain is often attributed to diffuse esophageal spasm (DES), in fact, this is a relatively rare esophageal motility disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal information available on the actual pathogenesis of diffuse spasm, underscoring the question of whether this manometric abnormality represents a distinct disorder. A study in five patients with DES suggested that these patients may have a malfunction in endogenous nitric oxide synthesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    degradation because a dose-dependent improvement in the peristaltic nature (increased latency period) of swallow-induced contractions occurred during intravenous glycerine trinitrate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/5\">",
"     5",
"    </a>",
"    ]. It has been observed that nitrates provide some benefit in the treatment of patients with DES [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a variety of motility patterns, such as \"high amplitude,\" repetitive, simultaneous, and prolonged duration contractions may be observed, the presence of excess numbers of simultaneous contractions in the distal esophagus is the hallmark of this form of dysmotility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These abnormalities can be quite sporadic in occurrence. Based upon the findings in normal volunteers, 20 percent or more simultaneous contractions found during standardized motility testing are considered necessary to suggest this diagnosis.",
"   </p>",
"   <p>",
"    Manometric findings in case series of patients with DES include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manometric findings consistent with DES were infrequent in a large number of patients being tested for either dysphagia or chest pain, with a prevalence of only about 3 percent in each group [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/10\">",
"       10",
"      </a>",
"      ]. These \"spastic\" contractions were invariably not of high amplitude, ie, above 180 mmHg, which represents the average upper limit in normal volunteers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The smooth muscle portion of the esophagus is primarily involved. In a study of 53 patients with DES who underwent proximal and distal esophageal manometry, simultaneous contractions were observed in 37 percent of swallows in the distal (smooth muscle) portion of the esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/11\">",
"       11",
"      </a>",
"      ]. In contrast, only 2 percent of swallows showed simultaneous contractions in the proximal (striated muscle) portion of the esophagus. The authors suggested that the term \"distal\" esophageal spasm was a more appropriate description for this condition.",
"     </li>",
"     <li>",
"      DES can be divided into two different clinical syndromes based upon the amplitude of the individual patient's simultaneous contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Patients with DES who present with chest pain have higher amplitudes and better transit of swallowed boluses on impedance testing than those who present with dysphagia.",
"     </li>",
"     <li>",
"      About one-third of patients with DES show associated abnormalities of lower esophageal sphincter function, either high resting pressure or incomplete relaxation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-resolution esophageal pressure topography (HREPT) in patients with suspected DES reveals simultaneous contractions in the distal esophagus with normal relaxation of the lower esophageal sphincter (",
"    <a class=\"graphic graphic_figure graphicRef82704 \" href=\"UTD.htm?7/57/8088\">",
"     figure 1",
"    </a>",
"    ). DES is characterized by a normal mean integrated relaxation pressure (IRP), &gt;20 percent premature contractions (distal latency &lt;4.5 seconds). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17785?source=see_link&amp;anchor=H1871924#H1871924\">",
"     \"High resolution manometry\", section on 'Distal esophageal spasm (DES)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings are quite variable in patients suspected of having DES. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiographic picture includes a broad spectrum of severe non-peristaltic contractions, which may produce striking abnormalities in the barium column. These findings have resulted in descriptions such as \"rosary bead\" or \"corkscrew\" esophagus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69821 \" href=\"UTD.htm?26/30/27118\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81244 \" href=\"UTD.htm?13/46/14062\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, radiographic studies may be entirely normal among patients with DES; as a result, these tests are neither specific nor sensitive. In one study, patients presenting with dysphagia were more likely to have abnormal bolus transit compared with those who presented with chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/13\">",
"     13",
"    </a>",
"    ]. This observation has led to the conclusion that a diagnosis of DES should be based upon associated clinical and manometric findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201458367\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of DES is outlined below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NUTCRACKER ESOPHAGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutcracker esophagus describes a manometric finding of high amplitude peristaltic contractions in the distal 10 cm of the esophagus, with average distal esophageal peristaltic pressures (ie, distal esophageal amplitude (DEA)) exceeding 220 mmHg after 10 or more 5 mL liquid swallows during standardized manometry testing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High resolution esophageal pressure topography reveals vigorous contractions with normal relaxation of the lower esophageal sphincter and propagation velocity (as opposed to DES, in which the contractions are simultaneous) (",
"    <a class=\"graphic graphic_figure graphicRef67976 \" href=\"UTD.htm?43/30/44521\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/2\">",
"     2",
"    </a>",
"    ]. The strength of the contractions in the distal esophagus is quantified by calculating the distal contractile integral (DCI) value. The DCI integrates the length, contractile amplitude, and duration of a contraction and is expressed as mmHgscm. A normal DCI value is 5000 mmHgscm or less (",
"    <a class=\"graphic graphic_table graphicRef59779 \" href=\"UTD.htm?14/23/14717\">",
"     table 3",
"    </a>",
"    ). Based on HREPT, a new subgroup of nutcracker esophagus has been described known as \"spastic nutcracker\" or \"jackhammer esophagus\". Patients with spastic nutcracker have distal contractile integral values of &gt;8000 mmHgscm, with repetitive high amplitude contractions that are associated with dysphagia or chest pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17785?source=see_link&amp;anchor=H1871168#H1871168\">",
"     \"High resolution manometry\", section on 'Hypertensive peristalsis (\"nutcracker esophagus\")'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17785?source=see_link&amp;anchor=H1561726#H1561726\">",
"     \"High resolution manometry\", section on 'Hypercontractile (jackhammer) esophagus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nutcracker esophagus may overlap with other esophageal motility disorders. Many patients with nutcracker esophagus also have a hypertensive or poorly relaxing lower esophageal sphincter. One study using ambulatory 24-hour esophageal manometry found that patterns of DES or nutcracker esophagus on stationary manometry would frequently switch categories at the time of pain episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies using high-frequency intraluminal ultrasound have demonstrated that the normally coordinated contractions of the circular and longitudinal muscle layers of the esophagus are asynchronous in patients with nutcracker esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The asynchrony was reversed after administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , suggesting that the pathogenesis of nutcracker esophagus is at least in part related to a hypercholinergic state [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is controversy regarding the relationship of nutcracker esophagus to symptoms. The manometric finding of nutcracker esophagus was noted in 12 percent of patients with unexplained chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/21\">",
"     21",
"    </a>",
"    ]. However, not all patients with nutcracker esophagus have chest pain. Those who do may have heightened visceral sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with higher (220 mmHg) average distal esophageal peristaltic contractions were more likely to present with chest pain and had less associated gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201458403\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nutcracker esophagus is outlined below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYPERTENSIVE LOWER ESOPHAGEAL SPHINCTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypertensive lower esophageal sphincter (LES) also represents a primary esophageal motility abnormality of the hypercontractile type. The hypertensive LES is defined as a resting, midrespiratory pressure greater than 45 mmHg based upon conventional manometry (CM) studies performed in normal volunteers (",
"    <a class=\"graphic graphic_figure graphicRef67976 \" href=\"UTD.htm?43/30/44521\">",
"     figure 2",
"    </a>",
"    ). However, when using high resolution esophageal pressure topography (HREPT), hypertensive LES is defined as a pressure greater than 35 mmHg (",
"    <a class=\"graphic graphic_table graphicRef59779 \" href=\"UTD.htm?14/23/14717\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some patients with a hypertensive LES also have incomplete relaxation. In two studies of patients with a hypertensive LES, nearly 50 percent of the patients also had the high amplitude distal peristaltic waves of the nutcracker esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to DES, hypercontracting motility abnormalities appear to be frequently associated with either high resting LES pressures or incomplete relaxation. Little is known about the potential pathophysiologic mechanisms in these hypercontractile disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201458474\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypertensive LES is outlined below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific therapies have been difficult to define, since both the actual pathophysiology and the relation of the motility findings to symptoms remain obscure. In addition, the relative rarity of definitive DES makes it unlikely that large controlled trials will be feasible.",
"   </p>",
"   <p>",
"    Multiple therapies have been suggested for these patients (",
"    <a class=\"graphic graphic_table graphicRef59816 \" href=\"UTD.htm?18/11/18619\">",
"     table 5",
"    </a>",
"    ). The large number of potential therapies indicates that the most effective treatment is yet to be defined; this difficulty may be a reflection of the different pathophysiologic mechanisms potentially involved in individual patients.",
"   </p>",
"   <p>",
"    There are minimal data available from prospective controlled observations and those that are positive have enrolled only small numbers of patients. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, double-blind crossover study found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      (60 to 90 mg four times daily) significantly relieved chest pain when compared with placebo in 22 patients with nutcracker esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/25\">",
"       25",
"      </a>",
"      ]. Another study found that diltiazem led to a reduction in dysphagia as well as chest pain, although compared to placebo this was not statistically significant, most likely due to the small number of patients included in this study [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two antidepressants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      (100 to 150",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      have been shown to be effective in controlled clinical trials in relieving chest pain in patients with esophageal motility abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. These drugs probably modify visceral sensory perception rather than specifically treating the dysmotility [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Botulinum toxin injection has been suggested for therapy of patients with \"non-achalasia\" abnormal esophageal motility [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/15,29,30\">",
"       15,29,30",
"      </a>",
"      ]. One of the largest series included 29 symptomatic patients who had been diagnosed with a spastic esophageal motility disorder (DES, hypertensive LES, or nutcracker esophagus) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/30\">",
"       30",
"      </a>",
"      ]. Patients were treated with 100 units of botulinum toxin injected at the Z-line (given as five circumferential injections of a 20",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      injection). A response (defined as at least a 50 percent reduction in chest pain) was observed in 70 percent of patients; 48 percent had complete relief of pain. The average duration of symptom relief was approximately seven months. The study had no control group.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      (50 mg once daily as needed) was associated with symptom relief in a group of 11 patients with nutcracker esophagus or DES [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/31\">",
"       31",
"      </a>",
"      ]. A case report described a patient with severe chest pain and high amplitude DES who responded to all three phosphodiesterase inhibitors (sildenafil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of seven patients with esophageal dysmotility, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"       bethanechol",
"      </a>",
"      was associated with increased contraction pressures and bolus transit times [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/33\">",
"       33",
"      </a>",
"      ]. The value of this approach requires further study.",
"     </li>",
"     <li>",
"      Uncontrolled observations have suggested that nitrates, anticholinergics, pneumatic dilatation, or an extended myotomy may be beneficial, although controlled studies of these approaches have not been conducted. One should be quite wary of subjecting patients to an extended myotomy for the treatment of unexplained chest pain, since the results of the treatment (ie, postoperative dysphagia) may be worse than the initial disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other data suggest nonpharmacologic methods of treatment may be beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hot water has been shown to improve esophageal clearance and decrease the amplitude and duration of esophageal body contractions in patients with motility disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/35\">",
"       35",
"      </a>",
"      ]. The benefit of hot liquids taken with meals was evaluated in an uncontrolled trial that included 48 patients with esophageal motility disorders who were followed for six months; 58 percent noted improvement in symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peppermint oil (a known smooth muscle relaxant) improved manometric abnormalities in a case series of eight patients with diffuse esophageal spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/36\">",
"       36",
"      </a>",
"      ]. Two patients also had improvement in chest pain. The clinical significance of these observations remains to be determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10098002\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that over time, many patients with diffuse esophageal spasm (DES) or nutcracker esophagus will show symptomatic improvement. In a survey study, patients with these esophageal motility disorders were compared with patients who had dysphagia or chest pain, but normal esophageal manometry and pH studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/37\">",
"     37",
"    </a>",
"    ]. After three to ten years of follow-up, mean symptom scores decreased significantly in patients with motility disorders compared with controls in whom there was no improvement. Mean scores decreased from 7.7 to 5.9 for patients with DES and from 8.0 to 5.3 for nutcracker esophagus. Specific treatments were reported to be helpful by 39 percent of patients with DES and 29 percent of patients with nutcracker esophagus. With the exception of antacids, no specific therapy was beneficial in more than one patient, and no patients reported a response to calcium channel blockers or nitrates. Interestingly, patients who found the esophageal manometry examination and the subsequent explanation of their symptoms helpful had a significant improvement in symptoms, whereas those who did not find the explanation helpful did not show an improvement, suggesting a possible psychologic component to symptom improvement.",
"   </p>",
"   <p>",
"    An association with psychologic symptoms was also noted in a study of 113 patients with abnormal esophageal motility, 23 symptomatic controls and 27 asymptomatic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/38\">",
"     38",
"    </a>",
"    ]. Compared with asymptomatic controls, increased somatization, acute anxiety, or depression was noted in patients with hypertensive lower esophageal sphincter, nutcracker esophagus, or hypotensive contractions. However, there was no difference when patients with achalasia or diffuse esophageal spasm were compared with asymptomatic controls.",
"   </p>",
"   <p>",
"    Some studies also suggest that manometric findings may change over time. Whether this variability is due to changes in esophageal motility over time or instead reflects the limitations of esophageal manometry is not clear.",
"   </p>",
"   <p>",
"    Studies in DES and nutcracker esophagus have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined 12 patients diagnosed with DES who underwent a second manometry after a mean of five years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/39\">",
"       39",
"      </a>",
"      ]. The second manometry diagnosed achalasia in one patient (eight percent), DES in seven patients (58 percent), normal motility in three patients (25 percent), and nutcracker esophagus in one patient (eight percent).",
"     </li>",
"     <li>",
"      A study of 23 patients with nutcracker esophagus included 17 patients who had had three or more motility studies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13096/abstract/40\">",
"       40",
"      </a>",
"      ]. Four of the 17 patients (24 percent) consistently had high amplitude pressures, three (18 percent) had a diagnosis of nutcracker esophagus only on the initial study, and 10 (59 percent) intermittently had pressures consistent with nutcracker esophagus. In 6 of the 23 patients (26 percent) changes in motility patterns were noted intermittently (one diffuse spasm and five nonspecific motility disorders).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is considerable controversy concerning the clinical significance of abnormal esophageal motility patterns and whether they cause or explain a patient's symptoms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may present with chest pain or dysphagia. However, esophageal obstruction should be excluded prior to considering the diagnosis of esophageal dysmotility in a patient who complains of dysphagia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptoms of esophageal motility abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With conventional manometry (CM) testing, diffuse esophageal spasm is identified by 20 percent or more simultaneous contractions (with amplitude &gt;30 mmHg). Nutcracker esophagus is identified by average peristaltic pressures exceeding 220 mmHg during 10 or more 5 mL liquid swallows. Hypertensive lower esophageal sphincter (LES) is identified by a resting lower esophageal pressure above 45 mmHg using CM. When using high resolution esophageal pressure topography (HREPT), hypertensive LES is defined as a pressure greater than 35 mmHg (",
"      <a class=\"graphic graphic_table graphicRef59779 \" href=\"UTD.htm?14/23/14717\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diffuse (or distal) esophageal spasm'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Nutcracker esophagus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypertensive lower esophageal sphincter'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncertainty exists regarding the optimal management of symptomatic patients with manometric profiles of diffuse spasm, nutcracker esophagus, or hypertensive LES. Our approach is summarized below:",
"      <br/>",
"      <br/>",
"      Patients whose primary symptom is chest pain &ndash; We suggest a calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      180 to 240",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or a tricyclic antidepressant (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      25 to 50 mg at bedtime) as the initial treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who do not respond to this treatment, treatment options include botulinum toxin or a nitric oxide contributing drug (eg, isosorbide 10 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      50 mg on an \"as needed\" basis for pain).",
"      <br/>",
"      <br/>",
"      Patients whose primary symptom is dysphagia &ndash; We suggest treatment with a calcium channel blocker (diltiazem 180 to 240",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/1\">",
"      Richter JE, Wu WC, Johns DN, et al. Esophageal manometry in 95 healthy adult volunteers. Variability of pressures with age and frequency of \"abnormal\" contractions. Dig Dis Sci 1987; 32:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/2\">",
"      Kahrilas PJ. Esophageal motor disorders in terms of high-resolution esophageal pressure topography: what has changed? Am J Gastroenterol 2010; 105:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/3\">",
"      Pandolfino JE, Ghosh SK, Rice J, et al. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol 2008; 103:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/4\">",
"      Kahrilas PJ, Ghosh SK, Pandolfino JE. Esophageal motility disorders in terms of pressure topography: the Chicago Classification. J Clin Gastroenterol 2008; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/5\">",
"      Konturek JW, Gillessen A, Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide? Scand J Gastroenterol 1995; 30:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/6\">",
"      Orlando RC, Bozymski EM. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med 1973; 289:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/7\">",
"      Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology 1977; 72:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/8\">",
"      CREAMER B, DONOGHUE E, CODE CF. Pattern of esophageal motility in diffuse spasm. Gastroenterology 1958; 34:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/9\">",
"      Richter JE, Castell DO. Diffuse esophageal spasm: a reappraisal. Ann Intern Med 1984; 100:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/10\">",
"      Dalton CB, Castell DO, Hewson EG, et al. Diffuse esophageal spasm. A rare motility disorder not characterized by high-amplitude contractions. Dig Dis Sci 1991; 36:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/11\">",
"      Sperandio M, Tutuian R, Gideon RM, et al. Diffuse esophageal spasm: not diffuse but distal esophageal spasm (DES). Dig Dis Sci 2003; 48:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/12\">",
"      Allen ML, DiMarino AJ Jr. Manometric diagnosis of diffuse esophageal spasm. Dig Dis Sci 1996; 41:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/13\">",
"      Tutuian R, Mainie I, Agrawal A, et al. Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry. Am J Gastroenterol 2006; 101:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/14\">",
"      DiMarino AJ Jr. Characteristics of lower esophageal sphincter function in symptomatic diffuse esophageal spasm. Gastroenterology 1974; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/15\">",
"      Miller LS, Parkman HP, Schiano TD, et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 1996; 41:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/16\">",
"      Campo S, Traube M. Lower esophageal sphincter dysfunction in diffuse esophageal spasm. Am J Gastroenterol 1989; 84:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/17\">",
"      Agrawal A, Hila A, Tutuian R, et al. Clinical relevance of the nutcracker esophagus: suggested revision of criteria for diagnosis. J Clin Gastroenterol 2006; 40:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/18\">",
"      Eypasch EP, Stein HJ, DeMeester TR, et al. A new technique to define and clarify esophageal motor disorders. Am J Surg 1990; 159:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/19\">",
"      Jung HY, Puckett JL, Bhalla V, et al. Asynchrony between the circular and the longitudinal muscle contraction in patients with nutcracker esophagus. Gastroenterology 2005; 128:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/20\">",
"      Korsapati H, Bhargava V, Mittal RK. Reversal of asynchrony between circular and longitudinal muscle contraction in nutcracker esophagus by atropine. Gastroenterology 2008; 135:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/21\">",
"      Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med 1987; 106:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/22\">",
"      Mujica VR, Mudipalli RS, Rao SS. Pathophysiology of chest pain in patients with nutcracker esophagus. Am J Gastroenterol 2001; 96:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/23\">",
"      Freidin N, Traube M, Mittal RK, McCallum RW. The hypertensive lower esophageal sphincter. Manometric and clinical aspects. Dig Dis Sci 1989; 34:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/24\">",
"      Waterman DC, Dalton CB, Ott DJ, et al. Hypertensive lower esophageal sphincter: what does it mean? J Clin Gastroenterol 1989; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/25\">",
"      Cattau EL Jr, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/26\">",
"      Drenth JP, Bos LP, Engels LG. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther 1990; 4:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/27\">",
"      Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/28\">",
"      Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/29\">",
"      Storr M, Allescher HD, R&ouml;sch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc 2001; 54:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/30\">",
"      Miller LS, Pullela SV, Parkman HP, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 2002; 97:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/31\">",
"      Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002; 50:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/32\">",
"      Agrawal A, Tutuian R, Hila A, Castell DO. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci 2005; 50:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/33\">",
"      Agrawal A, Hila A, Tutuian R, et al. Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J Clin Gastroenterol 2007; 41:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/34\">",
"      Stein HJ, DeMeester TR. Therapy of noncardiac chest pain: is there a role for surgery? Am J Med 1992; 92:122S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/35\">",
"      Triadafilopoulos G, Tsang HP, Segall GM. Hot water swallows improve symptoms and accelerate esophageal clearance in esophageal motility disorders. J Clin Gastroenterol 1998; 26:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/36\">",
"      Pimentel M, Bonorris GG, Chow EJ, Lin HC. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol 2001; 33:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/37\">",
"      Spencer HL, Smith L, Riley SA. A questionnaire study to assess long-term outcome in patients with abnormal esophageal manometry. Dysphagia 2006; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/38\">",
"      Song CW, Lee SJ, Jeen YT, et al. Inconsistent association of esophageal symptoms, psychometric abnormalities and dysmotility. Am J Gastroenterol 2001; 96:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/39\">",
"      Khatami SS, Khandwala F, Shay SS, Vaezi MF. Does diffuse esophageal spasm progress to achalasia? A prospective cohort study. Dig Dis Sci 2005; 50:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13096/abstract/40\">",
"      Dalton CB, Castell DO, Richter JE. The changing faces of the nutcracker esophagus. Am J Gastroenterol 1988; 83:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2256 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13096=[""].join("\n");
var outline_f12_50_13096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF ESOPHAGEAL MOTILITY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMS OF ESOPHAGEAL MOTILITY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFUSE (OR DISTAL) ESOPHAGEAL SPASM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201458367\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NUTCRACKER ESOPHAGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201458403\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYPERTENSIVE LOWER ESOPHAGEAL SPHINCTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201458474\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10098002\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2256\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2256|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/30/27118\" title=\"diagnostic image 1\">",
"      Diffuse esophageal spasm barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/46/14062\" title=\"diagnostic image 2\">",
"      Corkscrew esophagus barium swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2256|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/57/8088\" title=\"figure 1\">",
"      Diffuse esophageal spasm HREPT and manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/30/44521\" title=\"figure 2\">",
"      Nutcracker esophagus HREPT and manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2256|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/52/35660\" title=\"table 1\">",
"      Classification of primary esophageal motility abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/17/24859\" title=\"table 2\">",
"      Classification of secondary esophageal motility abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/23/14717\" title=\"table 3\">",
"      The Chicago Classification of esophageal motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/8/11404\" title=\"table 4\">",
"      Comparison of esophageal motility findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/11/18619\" title=\"table 5\">",
"      Therapies for DES and hypercontracting motility abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17785?source=related_link\">",
"      High resolution manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=related_link\">",
"      Pathophysiology and etiology of achalasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_50_13097="U-S choriocarcinoma and AVM A";
var content_f12_50_13097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56972%7EOBGYN%2F64599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56972%7EOBGYN%2F64599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound choriocarcinoma and AVM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choriocarcinoma: with associated arteriovenous malformation: Patient with choriocarcinoma after a molar pregnancy. Ultrasound shows a solid and cystic lesion in the myometrium adjacent to the endometrial cavity and measuring 3.0 x 2.5 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound choriocarcinoma and AVM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choriocarcinoma with associated arteriovenous malformation: Patient with choriocarcinoma and associated AVM. Color Doppler of the complex lesion in the myometrium reveals a large amount of swirling blood flow consistent with arterial-venous fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13097=[""].join("\n");
var outline_f12_50_13097=null;
var title_f12_50_13098="Dermatofibrosarcoma protuberans";
var content_f12_50_13098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatofibrosarcoma protuberans",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13098/contributors\">",
"     William M Mendenhall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Mark T Scarborough, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Franklin P Flowers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13098/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/50/13098/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/50/13098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatofibrosarcoma protuberans (DFSP) is an uncommon locally aggressive cutaneous soft tissue sarcoma. Approximately 85 to 90 percent of DFSPs are low grade, while the remainder contain a high-grade sarcomatous component (which is usually a fibrosarcoma, designated DFSP-FS), and are considered to be intermediate-grade sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"     1",
"    </a>",
"    ]. Although they rarely metastasize (fewer than 5 percent of cases), all DFSP variants have a propensity to recur locally.",
"   </p>",
"   <p>",
"    This topic review will focus on the clinical presentation, diagnosis, histology, molecular pathogenesis, and treatment of DFSP. Issues specific to DFSP arising in the head and neck region are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H29#H29\">",
"     \"Head and neck sarcomas\", section on 'Desmoids and dermatofibrosarcoma protuberans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DFSP is a relatively rare tumor, with only 0.8 to 4.5 cases per million persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In the United States, DFSP accounts for between 2 and 6 percent of all soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and 18 percent of all cutaneous soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/4\">",
"     4",
"    </a>",
"    ]. In a series of 12,114 cutaneous soft tissue sarcomas reported to the Surveillance, Epidemiology and End Results (SEER) registry from 1992 through 2004, DFSP was second only to Kaposi's sarcoma (which accounted for 71 percent of cases).",
"   </p>",
"   <p>",
"    The Bednar or pigmented variant (distinguished by the dispersal of melanin-containing cells in an otherwise typical DFSP) is even less common. It represents only 5 percent of all DFSP cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], and predominantly occurs in black persons.",
"   </p>",
"   <p>",
"    DFSP most often arises in adults in their thirties [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,10\">",
"     1,10",
"    </a>",
"    ], but has been described in children and in the elderly; rarely it presents congenitally [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,8,11-13\">",
"     1,8,11-13",
"    </a>",
"    ]. In one large series, children accounted for 6 percent of all cases of DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/14\">",
"     14",
"    </a>",
"    ]. In some reports, patients with DFSP-FS are older (median age 56 versus 37 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/15\">",
"     15",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic feature of DFSP is the presence of a specific cytogenetic abnormality. DFSP cells possess either a unique translocation involving chromosomes 17 and 22, which is most often unbalanced, or supernumerary ring chromosomes, which are derived from chromosome 22 and contain low level amplified sequences from 17q22-qter and 22q10-q13.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the ring chromosomes and the translocated linear derivative chromosome 22 contain a unique fusion gene in which the gene for platelet-derived growth factor B (PDGF-B) is fused with the highly expressed collagen type 1A1 (COL1A1) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This places the PDGFB gene under the control of the COL1A1 promoter, and results in deregulated expression of PDGFB and continuous autocrine activation of the PDGF receptor b (PDGFRb), a tyrosine kinase receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This molecular alteration is thought to be fundamental to the development of DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/20\">",
"     20",
"    </a>",
"    ]. Using sensitive molecular techniques such as multiplex reverse-transcriptase polymerase chain reaction (RT-PCR) to detect fusion transcripts for all possible COL1A1 breakpoints in conjunction with FISH, the fusion gene can be demonstrated in nearly all cases of DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/23\">",
"     23",
"    </a>",
"    ]. The detection of the COL1A1-PDGFB fusion product by RT-PCR may be useful diagnostically (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Histology and histogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In some cases, the clonal evolution from DFSP to a DFSP-FS (or, less commonly, DFSP with areas of pleomorphic sarcoma) involves genomic gains in the COL1A1-PDGFB fusion gene [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. However, this finding is not observed universally. Others describe the early development of microsatellite instability (MSI), and the later acquisition of p53 mutations in cases with a high-grade sarcoma component [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. As an example, Japanese investigators analyzed MSI and p53 mutations in 44 tumors from 36 patients with either DFSP (n = 27) or DFSP-FS (n = 9) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/26\">",
"     26",
"    </a>",
"    ]. A high rate of MSI occurred significantly more often in DFSP-FS compared with DFSP (4 of 9 versus 1 of 27 patients). Mutational analysis revealed ten p53 point mutations in six patients, four of which were missense mutations and six silent. Three of the four missense mutations were found in the DFSP-FS group compared with only one in the DFSP group.",
"   </p>",
"   <p>",
"    The constitutive activation of the tyrosine kinase receptor PDGFRb in the majority of cases provides the rationale for targeted inhibition of this pathway as a potential treatment strategy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Molecularly targeted therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOLOGY AND HISTOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, DFSP is composed of monomorphic, benign-appearing spindle cells arranged in an irregularly whorled or storiform pattern said to resemble a straw mat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/27\">",
"     27",
"    </a>",
"    ]. The cells intersect in tight right angles around central vessels, and early lesions may have a narrow tumor-free zone (Grenz Zone) between the tumor and epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, an uncommon variant is the Bednar tumor, in which there are melanin-containing dendritic cells interspersed among the spindle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Other variants are myxoid DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/28\">",
"     28",
"    </a>",
"    ], which is characterized by cellular areas with interstitial mucin (and which may be difficult to differentiate from a myxoid liposarcoma), and the atrophic type [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/2,8,29\">",
"     2,8,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 10 to 15 percent of tumors contain a high-grade sarcomatous component that is usually, but not inevitably, a fibrosarcoma (hence the abbreviation DFSP-FS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,30-32\">",
"     1,30-32",
"    </a>",
"    ]. The sarcomatous component typically occupies between 20 and 80 percent of the tumor (median, 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/32\">",
"     32",
"    </a>",
"    ]. The spindle cells in the sarcomatous areas show marked nuclear pleomorphism, and the mitotic rate is usually (but not always) higher than in the typical DFSP component [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/32\">",
"     32",
"    </a>",
"    ]. Immunohistochemical staining for CD34 is often lost in the sarcomatous component (see below).",
"   </p>",
"   <p>",
"    The presence of a sarcomatous component increases the tumor grade from low to intermediate, but the impact on overall prognosis is debated. Most [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/15,33-36\">",
"     15,33-36",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/32,37\">",
"     32,37",
"    </a>",
"    ] series suggest a higher rate of metastases and a worse prognosis in these patients. The impact of a sarcomatous component on local recurrence rates (especially in patients who undergo optimal surgery) is even less clear (see",
"    <a class=\"local\" href=\"#H18\">",
"     'RT following surgical resection'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, examination of a hematoxylin and eosin-stained specimen by light microscopy provides an unequivocal diagnosis. However, It may be difficult to distinguish DFSP histologically from other mesenchymal neoplasms such as a dermatofibroma (the fibrous type of benign fibrous histiocytoma), fibromatosis (desmoid tumor), fibrosarcoma, leiomyosarcoma, pleomorphic sarcoma, not otherwise specified, or fibroxanthoma. In such cases, immunohistochemical staining (IHC) or even molecular diagnostic testing for the characteristic fusion gene may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;DFSP usually stains positively for CD34, hyaluronate, and vimentin, and negatively for factor XIIIa (",
"    <a class=\"graphic graphic_table graphicRef73370 \" href=\"UTD.htm?6/37/6749\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/2,27,38,39\">",
"     2,27,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD34 is one of the most useful stains to differentiate DFSP from dermatofibroma and other soft tissue tumors. The spindle cells of DFSP stain positively with CD34, while dermatofibromas are usually CD34- negative. In fact, the finding of CD34 positivity has renewed the debate over the cellular origins of DFSP (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Histogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Unfortunately, the reliability of CD34 staining is not absolute. The sensitivity of CD34 IHC in DFSP ranges from 84 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/27,38-40\">",
"     27,38-40",
"    </a>",
"    ], while between 2.5 and 5 percent of dermatofibromas stain positively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/27,40\">",
"     27,40",
"    </a>",
"    ]. There are also reports of loss of CD34 expression with the transition of DFSP to DFSP-FS, and in myxoid DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/32,41\">",
"     32,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recent study suggests utility for IHC staining for hyaluronate (the major component of extracellular matrix) and CD44 (a membrane glycoprotein thought to be its cell surface receptor) in the differential diagnosis of dermatofibroma and DFSP. The cells of dermatofibromas tend to stain intensely for CD44, while its stroma stains faintly for hyaluronate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, DFSP tends to be strongly positive for hyaluronate, while CD44 is significantly reduced or absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Molecular diagnostics",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, over 90 percent of cases of DFSP have a characteristic unbalanced translocation between chromosomes 17 and 22 that places the PDGFB gene under the control of the COL1A1 promoter. The fusion transcript of this chimeric gene can be identified using RT-PCR. Molecular testing may be useful if the diagnosis is in doubt, or to predict the likelihood of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of locally advanced, recurrent, and metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The molecular pathogenesis of DFSP is discussed in detail above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact type of dermal mesenchymal cell from which DFSP arises is debated. Until recently, the histochemical and electron microscopic evidence seemed to point toward a fibroblastic origin, because DFSP cells stain uniformly for vimentin and contain active endoplasmic reticulum that synthesizes collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, the finding of CD34 positivity in DFSP has raised the possibility that dendritic cells in the skin may be responsible, possibly those derived from circulating hematopoietic progenitor cells. CD34 is a surface antigen that is expressed on normal hematopoietic stem cells which seems to be involved in the process of leukocyte adhesion to the vascular endothelium and in the control of immune responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IHC staining characteristics suggest that in normal skin, there appear to be at least three different kinds of dermal mesenchymal cells, other than endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       CD34-negative/factor",
"      </span>",
"      XIIIa-negative, as in the majority of fibroblasts in the reticular dermis",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD34-negative/factor",
"      </span>",
"      XIIIa-positive, as in dermatofibromas",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD34-positive/factor",
"      </span>",
"      XIIIa-negative, as in DFSP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In normal skin, the CD34-positive cells are a distinct population of spindle-shaped cells that are present in a perivascular, perifollicular, and peri-sweat gland distribution, and on interstitial dermal and subcutaneous dendritic cells. It is speculated that these dendritic cells might directly evolve from circulating hematopoietic progenitor cells that have become skin-associated and that they represent the cell of origin of DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/47\">",
"     47",
"    </a>",
"    ]. This is an area of ongoing investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early DFSP lesions are plaque-like areas of cutaneous thickening that are frequently violet-red or blue at the margins. DFSP is often described as skin-colored, red-brown, or violaceous. Rarely, they arise within a preexisting scar or tattoo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/9,48-50\">",
"     9,48-50",
"    </a>",
"    ]. DFSPs may also arise in the subcutaneous tissues, sometimes as a breast mass [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the tumor slowly enlarges, it becomes raised, firm, and nodular; the surrounding skin may be telangiectatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/10\">",
"     10",
"    </a>",
"    ]. The nodule is often fixed to the dermis but moves freely over deeper tissues. Fixation to deeper structures is observed late in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/10\">",
"     10",
"    </a>",
"    ]. Untreated, DFSP can attain massive dimensions, producing the large \"protuberant\" nodules for which it is named. However, at the time of diagnosis, most tumors are superficial (77 percent in one series of 159 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"     1",
"    </a>",
"    ]) and less than 5 cm in diameter (84 percent in the same series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"     1",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    The majority of DFSPs exhibit an indolent growth pattern, and in most cases, the lesion has been present for years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/10,33\">",
"     10,33",
"    </a>",
"    ]. Indolent growth, coupled with the rarity of DFSP and the variability in clinical appearance, contributes to diagnostic delay. As is seen with desmoid tumors, accelerated growth may occur during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common location for a DFSP is on the trunk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The following site distribution was observed in a series of 853 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trunk &mdash; 47 percent",
"     </li>",
"     <li>",
"      Lower extremity &mdash; 20 percent",
"     </li>",
"     <li>",
"      Upper extremity &mdash;18 percent",
"     </li>",
"     <li>",
"      Head and neck &mdash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis usually requires a core needle or incisional biopsy. For de novo, previously untreated tumors, fine needle aspirate (FNA) biopsy does not satisfactorily provide enough tissue to render an accurate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, FNA may be useful to establish the diagnosis of recurrent disease in a previously treated patient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Staging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most DFSPs are superficial, and tumor extent and mobility as well as regional node assessment are usually assessed by physical examination. Because of the rarity of both lymphatic and hematogenous dissemination, an extensive staging workup is usually unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For purposes of treatment planning, magnetic resonance imaging (MRI) is useful to determine the deep extent of the tumor, particularly with large or recurrent lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/11,60\">",
"     11,60",
"    </a>",
"    ]. On conventional T1-weighted images, DFSP can be isointense, hypointense, or hyperintense compared to normal skeletal muscle and typically has a lower signal intensity than subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/60\">",
"     60",
"    </a>",
"    ]. On T2-weighted images, there may be higher signal intensity as compared to fat, or an intermediate signal intensity that is similar to fat.",
"   </p>",
"   <p>",
"    Computed tomography (CT) scanning is not indicated except if underlying bone involvement is suspected. As noted above, because of the rarity of metastatic disease, an extensive radiographic staging workup is not routinely indicated unless suspicion is raised by the history or physical examination. Occasional patients have pulmonary metastases, particularly if the primary lesion is advanced, recurrent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intermediate grade. We usually get a chest x-ray preoperatively in all patients, and preferentially order chest CT for those with advanced, unfavorable tumors of prolonged duration or if the tumor has sarcomatous transformation (DFSP-FS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Staging systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other soft tissue sarcomas, most clinicians stage DFSP and DFSP-FS according to the American Musculoskeletal Tumor Society (MSTS) staging system, which is based upon histologic grade (using a two-tiered system, low versus high) and whether the tumor is confined to an anatomic compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage IA &mdash; Low-grade DFSP or intermediate-grade DFSP-FS that is within the",
"      <span class=\"nowrap\">",
"       cutaneous/subcutaneous",
"      </span>",
"      compartment and can be managed adequately by a wide excision alone (ie, dissection outside of the reactive zone)",
"     </li>",
"     <li>",
"      Stage IB &mdash; Low-grade DFSP or intermediate-grade DFSP-FS that has extended outside of an anatomic compartment (ie, into underlying fascia or muscle)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The designation of stage II disease in the MSTS staging system implies high-grade histology and does not apply to DFSP or DFSP-FS.",
"   </p>",
"   <p>",
"    There is an American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) staging system for soft tissue sarcomas, but it was only with the most recent 2010 edition that DFSP has been included as a histologic type for this site (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H351701269#H351701269\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the 2010 modification is controversial. Compared to the older 2002 version of the staging criteria (",
"    <a class=\"graphic graphic_table graphicRef69154 \" href=\"UTD.htm?10/30/10733\">",
"     table 3",
"    </a>",
"    ), the 2010 modification (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"     table 2",
"    </a>",
"    ) reclassified regional nodal involvement from stage IV to stage III disease. However, features of primary tumor classification in the 2002 edition were not maintained in the 2010 version. Specifically, the inclusion of both superficial and deep tumors within the same prognostic groups for tumors of the same size eliminates a criterion that previously stratified patient risk, without supporting data to suggest it is unnecessary.",
"   </p>",
"   <p>",
"    Another problem shared by both the 2002 and the 2010 classifications is that sarcomas over 10 cm in size have a greater risk of recurrence than do those 5 to 10 cm in size; both editions only stratify primary tumor stage as &le;5 versus &gt;5 cm in size.",
"   </p>",
"   <p>",
"    In Germany, a clinical staging system was described in the Short German Guidelines for DFSP, but the clinical utility is unclear, as the vast majority of tumors fall into the stage I category [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; Local tumor involvement",
"     </li>",
"     <li>",
"      Stage II &mdash; Lymph node metastases",
"     </li>",
"     <li>",
"      Stage III &mdash; Distant metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred initial treatment is resection with pathologically negative margins. Tumor size and location dictate the most appropriate surgical procedure. Given that metastases to lymph nodes are extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/64\">",
"     64",
"    </a>",
"    ], there is no role for prophylactic regional node dissection.",
"   </p>",
"   <p>",
"    Despite optimal MRI evaluation, the extent of local invasion is often difficult to appreciate clinically. This fact, combined with the rarity and heterogeneous clinical appearance of DFSP, often leads to inadequate initial resection. The risk of a local recurrence is as high as 50 percent with simple excision (\"conservative\" surgical margins) and is higher if the margins are positive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,65-67\">",
"     1,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of resection margins was shown in a series of 159 patients (134 DFSP, 25 DFSP-FS) treated at Memorial Sloan-Kettering over a 48-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"     1",
"    </a>",
"    ]. The resection margins were involved in 51 patients (32 percent), close (&lt;1 mm) in 15 (10 percent), and otherwise negative in 93 (58 percent). With a median follow-up of 57 months, there were 34 recurrences, 29 of which developed in patients with positive or close margins. Recurrences were also significantly more frequent in patients with DFSP-FS (13 of 25, 52 percent) as compared to DFSP (21 of 134, 16 percent).",
"   </p>",
"   <p>",
"    Although localized recurrences can frequently be salvaged with further surgery, locally recurrent tumors have a significant propensity for deep invasion into the fascia, muscle, or bone, which increase the risk for both inadequate resection and functional as well as cosmetic defects. Furthermore, local recurrence predisposes to distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,33,68,69\">",
"     1,33,68,69",
"    </a>",
"    ]. In the above noted series, both patients who developed fatal metastatic disease had initially incompletely resected DFSP-FS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"     1",
"    </a>",
"    ]. For all of these reasons, marginal resection should be avoided, and histologic assessment of the final resection margins is mandatory [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Wide local excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide local excision (WLE) is an option for surgical management, and preferred over marginal excision for both DFSP and DFSP-FS. However, even with WLE, local recurrence rates range from 4 to 42 percent, and averaging 6 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,5,57,68,70-75\">",
"     1,5,57,68,70-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much of the variability relates to the width of the resection margin. Mapping with Mohs micrographic surgery has revealed tentacle-like tumor projections that often extend beyond 3 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/76\">",
"     76",
"    </a>",
"    ]. In a series of 66 French patients treated for DFSP between 1982 and 2002, local recurrences were significantly more frequent among those with a resection margin of &lt;3 cm, as compared to margins from 3 to 5 cm (47 versus 7 percent).",
"   </p>",
"   <p>",
"    These data form the basis of the general recommendation that the resection margins be at least 3 cm (down to and including the fascia), and as wide as 5 cm, depending on the primary tumor size [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/71,77,78\">",
"     71,77,78",
"    </a>",
"    ]. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend margins of 2 to 4 cm, to the investing fascia of muscle or pericranium with clear pathologic margins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/79\">",
"     79",
"    </a>",
"    ]. However, in practice, such margins are rarely possible without significant cosmetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional deficit, particularly in anatomically challenging areas such as the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H29#H29\">",
"     \"Head and neck sarcomas\", section on 'Desmoids and dermatofibrosarcoma protuberans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, others suggest that very low local recurrence rates (1 percent) and a high rate of primary closure (69 percent) can be achieved with narrower margins (median 2 cm, range 0.5 to 3 cm), as long as the surgical approach is standardized and pathologic evaluation of the margins is meticulous [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/80\">",
"     80",
"    </a>",
"    ]. In this multi-institutional retrospective series of 204 patients undergoing WLE for a DFSP, 81 percent achieved negative margins with only one excision, 16 percent required two surgeries, 3 percent required three, and 1 percent, four resections.",
"   </p>",
"   <p>",
"    If positive margins are diagnosed after surgery, most guidelines recommend reresection, followed by adjuvant RT (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mohs micrographic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to WLE, Mohs micrographic surgery (MMS) is increasingly used for resection of large or recurrent DFSP, and those arising in anatomically challenging areas such as the head or neck. In contrast to WLE, which uses representative vertical sectioning, MMS requires continuing sequential horizontal sectioning during the resection with immediate microscopic examination of the resected tissue by frozen section until a clear margin is obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H29#H29\">",
"     \"Head and neck sarcomas\", section on 'Desmoids and dermatofibrosarcoma protuberans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high probability of cure of DFSP can be attained with MMS, as long as the final margins are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/72,73,81-88\">",
"     72,73,81-88",
"    </a>",
"    ]. Although randomized trials have not been conducted, the available data from nonrandomized comparative and noncomparative studies suggest that local recurrence rates are lower after MMS than after WLE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/75,88\">",
"     75,88",
"    </a>",
"    ]. In a systematic review of 23 nonrandomized trials focusing on recurrence rates among patients undergoing MMS or WLE for DFSP, the local recurrence rate after MMS was 1.11 percent (95% CI 0.02-6.03) versus 6.32 percent (95% CI 3.19-11.02) for WLE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the main benefits of MMS is the ability to minimize surgical margins, thus preserving cosmetically and functionally vital tissue. As noted above, while there is controversy regarding the optimal width of the surgical margins with WLE, they are generally 2 to 4 cm; in the systematic review described above, a median maximum lateral margin of 1 to 2 cm resulted in complete excision of most tumors treated with MMS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data have led many to consider MMS as the preferred surgical approach for DFSP because of its high cure rate and ability to preserve normal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/72,86,89\">",
"     72,86,89",
"    </a>",
"    ]. However, some argue that MMS is histologically inadequate since on paraffin sections, minimal residual DFSP cells cannot be clearly differentiated from scattered spindle cells in normal dermis, scar or connective tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/90\">",
"     90",
"    </a>",
"    ]. There are no randomized trials that demonstrate the superiority of this modality over other surgical methods, and in particular, there is a lack of long-term data on MMS, which is important given that the median time to recurrence is approximately five years post surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, the available data support the concept of Moh&rsquo;s as equal or better to WLE for treatment of DFSP, at least in the short term. Wide local excision with 2 to 4 cm margins and histologic margin confirmation is still an acceptable procedure in guidelines published by the NCCN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/79\">",
"     79",
"    </a>",
"    ]. Another option is a modified Mohs procedure, in which the Mohs technique includes an additional final margin for permanent section assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although DFSP is a radioresponsive tumor, radiation therapy (RT) is only rarely used as a primary treatment. There are scant data pertaining to the efficacy of RT when used alone for gross disease (",
"    <a class=\"graphic graphic_table graphicRef67515 \" href=\"UTD.htm?35/60/36812\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/65,91\">",
"     65,91",
"    </a>",
"    ]. In an early series, all three patients treated with RT (67 to 75 Gy) after an intralesional excision remained locally controlled at 85, 106, and 108 months posttreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/65\">",
"     65",
"    </a>",
"    ]. However, in a second report, a single patient who received RT alone for gross disease recurrence after surgery did not achieve disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/91\">",
"     91",
"    </a>",
"    ]. These data suggest that RT is not a substitute for inadequate resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     RT following surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the absence of randomized clinical trials proving benefit, adjuvant RT is commonly recommended in conjunction with wide local resection of large tumors, or when the surgical margins are close or positive and further surgery is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/10,65,79,91-94\">",
"     10,65,79,91-94",
"    </a>",
"    ]. Whether administered before or after surgery, RT significantly reduces the risk of a local recurrence.",
"   </p>",
"   <p>",
"    Several retrospective series have been reported, primarily of patients undergoing local excision with or without RT (",
"    <a class=\"graphic graphic_table graphicRef67515 \" href=\"UTD.htm?35/60/36812\">",
"     table 4",
"    </a>",
"    ). The benefit of RT can be illustrated by our experience with 35 patients with DFSP of the trunk and extremities (18 untreated, 17 recurrent) treated surgically at the University of Florida between 1975 and 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/10\">",
"     10",
"    </a>",
"    ]. Thirty-four had been initially operated on elsewhere with inadequate procedures (either marginal or intralesional resections). The margins at reexcision were wide in 28 patients, marginal in six, and intralesional in one patient. Of the seven patients with inadequate surgical margins, four received adjuvant RT.",
"   </p>",
"   <p>",
"    With a median follow-up of 58 months, all 28 patients undergoing WLE were locally controlled, as were the four patients with inadequate margins who received adjuvant RT (mean, 57.5 Gy; range, 50 to 65 Gy). Three patients with inadequate margins who did not receive RT recurred locally; all were successfully salvaged with further surgery, and none developed metastatic disease.",
"   </p>",
"   <p>",
"    These data support the view that conservative resection and postoperative RT could be considered in situations where adequate WLE alone would result in major cosmetic or functional deficits, particularly if the expertise to perform Mohs micrographic surgery is not available.",
"   </p>",
"   <p>",
"    The presence of a sarcomatous component within the tumor (ie, DFSP-FS) is not, by itself, viewed as an indication for postoperative RT. While the overall rate of distant metastases and prognosis overall is worse, whether tumors that contain a sarcomatous component have a worse local recurrence rate is unclear. Although some series suggest that local control rates are worse for patients with DFSP-FS compared to conventional DFSP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,33\">",
"     1,33",
"    </a>",
"    ], others do not, as long as surgical excision is adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/15,32,74\">",
"     15,32,74",
"    </a>",
"    ]. NCCN guidelines do not suggest RT for tumors with a sarcomatous component unless the tumor is large or the margins are close or positive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose-fractionation schedules and treatment techniques for adjuvant RT of DFSP are similar to those used for other soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, the prognosis is good. Patients rarely die from DFSP, but morbidity due to local recurrence remains a problem. In addition to positive resection margins, age over 50 appears to be a risk factor for local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"     1",
"    </a>",
"    ]. Tumor size is not a risk factor for local recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of local recurrences become evident within three years, but 25 to 30 percent develop after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/1,5,81,96,97\">",
"     1,5,81,96,97",
"    </a>",
"    ]. Thus, posttreatment follow-up must be carried out lifelong. More frequent examinations are usually undertaken in the first three years after treatment.",
"   </p>",
"   <p>",
"    The optimal surveillance strategy has not been established. Guidelines from the NCCN recommend only that the primary site be examined every 6 or 12 months, and that the patient be educated as to regular self examination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALLY ADVANCED, RECURRENT, AND METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, metastasis to lymph nodes is extremely rare, with only a few case reports in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/64\">",
"     64",
"    </a>",
"    ]. &nbsp;The management strategy for patients with LN metastases is controversial. However, lymphadenectomy is recommended in such cases, as long-term survival is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distant hematogenous metastases are even more rare and are most likely in patients who have had multiple local recurrences after inadequate surgical resection. The lungs are most frequently affected, but metastases to brain, bone and other soft tissues are reported. Resection should be strongly considered for isolated, potentially resectable metastatic disease, especially isolated pulmonary metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/15,99\">",
"     15,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, the vast majority (possibly all) cases of DFSP have a characteristic chromosomal translocation, t(17;22), which places platelet-derived growth factor beta (PDGFB) under the control of the COL1A1 promoter. This results in constitutive activation of the PDGF receptor beta (PDGFRB), a tyrosine kinase.",
"   </p>",
"   <p>",
"    Orally active small molecule tyrosine kinase inhibitors (TKIs) have been developed that target such molecular defects. One such agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (Gleevec&reg;) inhibits the PDGFR as well as other receptor tyrosine kinases such as c-kit and has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , are multifunctional TKIs that inhibit the PDGFR, among other tyrosine kinases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating reports suggest that most patients with advanced DFSP and the characteristic translocation benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , and some have a sustained complete clinical remission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/18,43,100-104\">",
"     18,43,100-104",
"    </a>",
"    ]. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest retrospective series, 10 patients with locally advanced (n = 8) or metastatic (n = 2) DFSP received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      800 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/100\">",
"       100",
"      </a>",
"      ]. All eight patients with locally advanced disease had karyotypic or FISH (fluorescence in situ hybridization) evidence of t(17;22), and all responded to therapy, two completely. The two patients with metastatic disease had more complex karyotypes. One who had the typical t(17;22) had a partial response that lasted seven months, while the second lacked the t(17;22) and did not respond.",
"     </li>",
"     <li>",
"      Two multicenter prospective phase II trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      for t(17;22)-positive locally advanced or metastatic DFSP were terminated early because of poor accrual after 2007, the year that imatinib was approved for treatment of DFSP by the US Food and Drug Administration [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/103\">",
"       103",
"      </a>",
"      ]. The North American trial (n = 8) used imatinib 400 mg daily, while the European trial (n = 16) used imatinib 400 mg twice daily. In a combined analysis of all 24 patients, there were 11 partial responses (46 percent), and nine others had stable disease. There did not seem to be an advantage for the higher imatinib dose. The median time to progression was 1.7 years.",
"     </li>",
"     <li>",
"      In published reports, the majority (12 of 17 cases) of DFSP-FS and three of three cases of DFSP with a pleomorphic sarcoma component had the fusion gene, and an excellent clinical response has been noted in such patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/22,24,25,43,100,101,104\">",
"       22,24,25,43,100,101,104",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although limited to only a few cases, conventional DFSP tumors lacking the 17,22 translocation do not seem to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/43,100\">",
"     43,100",
"    </a>",
"    ]. However, there is at least one case report documenting a partial response to imatinib in a patient with a locally advanced scalp DFSP-FS that was negative for t(17;22) by RT-PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/105\">",
"     105",
"    </a>",
"    ]. NCCN guidelines suggest molecular analysis using cytogenetics prior to the institution of imatinib.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Neoadjuvant and adjuvant imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of sustained complete clinical remission in patients with metastatic DFSP have prompted interest in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the neoadjuvant setting for large unresectable or recurrent tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/43,106-110\">",
"     43,106-110",
"    </a>",
"    ]. Early results from the two largest series are described in detail:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of eight patients with locally advanced DFSP treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (400 mg twice daily), two of the four complete responses were confirmed by surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/100\">",
"       100",
"      </a>",
"      ]. Four clinical PRs were subsequently rendered disease-free by surgery, and there was no evidence of progression at 1, 4,12, and 18 months postresection.",
"     </li>",
"     <li>",
"      In a French phase II trial of neoadjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , 25 adults with DFSP (20 primary, five recurrence disease) received two months of imatinib (600 mg daily) prior to wide local excision [",
"      <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/111\">",
"       111",
"      </a>",
"      ]. The COL1A1-PDGFB fusion gene was detected in 21 of 25 patients. A clinical response was noted in only nine patients (36 percent); it is possible that a longer duration of neoadjuvant treatment might prove beneficial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term results are not available from any report.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is approved in the US and Europe for use in adult patients who have unresectable, recurrent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic DFSP. This broad indication covers the use of imatinib as an alternative to RT for locally advanced, unresectable disease, including cases in which wide surgical excision is not feasible or a postoperative complication or wound healing is a concern, and as an alternative to primary RT for patients with locally recurrent but potentially resectable disease for whom reresection would result in unacceptable function or cosmetic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/79\">",
"     79",
"    </a>",
"    ]. A reduced tumor burden might permit a more conservative surgical procedure to be undertaken at a later time.",
"   </p>",
"   <p>",
"    The optimal duration of neoadjuvant therapy and the appropriate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    dose remain unanswered questions. Several phase II studies of neoadjuvant imatinib are ongoing, and eligible patients should be encouraged to enroll [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are also needed to determine the value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in cases of positive margins after surgical excision or in patients with other risk factors for recurrence after complete resection (such as the presence of the DFSP-FS variant). However, given the lack of data regarding benefit of imatinib in any of these settings, and the generally good prognosis of patients with resected DFSP, adjuvant imatinib should only be considered in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Other tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it would seem likely that other tyrosine kinase inhibitors that target PDGFR (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ) would also be beneficial for DFSP, there is no published experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Conventional chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available. The available data suggest a lack of responsiveness of DFSP to the combination chemotherapy regimens that are used in other soft tissue sarcomas (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/91,104,114\">",
"     91,104,114",
"    </a>",
"    ]. However, at least one case report suggests responsiveness of advanced DFSP to low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , a similar regimen that is used for patients with desmoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/50/13098/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatofibrosarcoma protuberans (DFSP) is a rare low- to intermediate-grade cutaneous sarcoma with little metastatic potential but a significant propensity for local recurrence. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A characteristic feature of DFSP is the presence of a specific cytogenetic abnormality, a translocation involving chromosomes 17 and 22, t(17;22). The deregulation of expression of platelet-derived growth factor-beta (PDGFB) produces continuous autocrine activation of the PDGF receptor b (PDGFRB), a tyrosine kinase. This provides both a unique molecular diagnostic test for DFSP, and the rationale for targeted inhibition of this pathway as a potential treatment strategy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Molecular pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal treatment for patients with localized DFSP is complete resection with negative margins. Every attempt should be made to achieve negative margins at the initial surgical treatment. Although many patients with locally recurrent disease can be salvaged by further surgery, the risk of functional deficits and metastatic disease is increased in such patients.",
"     </li>",
"     <li>",
"      One option is wide local excision (WLE). The optimal width of the resection margin is controversial, and often compromised by the proximity of critical structures especially in anatomically challenging areas such as the head and neck. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Wide local excision'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest adjuvant RT to improve the likelihood of local control in patients with close or positive margins after WLE (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, if the margins are positive, reresection is preferred, if feasible without major cosmetic or functional compromise. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'RT following surgical resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mohs micrographic surgery (MMS) is an alternative surgical approach for large",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent tumors and those that arise in anatomically confined areas where maximal preservation of normal tissue is desirable. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Mohs micrographic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the rare patient with lymph node involvement, we suggest lymphadenectomy because of the possibility of long-term relapse-free survival (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of locally advanced, recurrent, and metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resection should also be strongly considered for isolated, potentially resectable sites of metastatic disease, especially isolated pulmonary metastatic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"       \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      , an orally active small molecule tyrosine kinase inhibitor, can induce tumor regression in patients with recurrent unresectable",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic DFSP that harbors the characteristic molecular defect t(17;22). Although indications for imatinib are evolving, it is approved in the US and Europe for use in adult patients who have unresectable, recurrent,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic DFSP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest that molecular testing be carried out prior to the institution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and that use of imatinib be restricted to patients who carry the characteristic molecular defect (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). If testing is not available, then a therapeutic trial of imatinib seems reasonable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Further studies are needed to address whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      can be incorporated into surgical management of localized DFSP to permit a more conservative surgical resection, further reduce local and distant recurrence rates, and improve survival. Participation in a clinical trial is preferred. If patients are not eligible, or if a protocol is not available, it seems reasonable to try initial imatinib for patients in the following clinical situations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inoperable presentations, including cases in which wide surgical excision is not feasible or a postoperative complication or wound healing is a concern",
"     </li>",
"     <li>",
"      Recurrent disease where unacceptable functional or cosmetic defects will result from reresection",
"     </li>",
"     <li>",
"      Extensive advanced locoregional disease to reduce tumor burden, possibly allowing a more conservative surgical procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our view, adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    should be restricted to clinical trials until further information becomes available.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/1\">",
"      Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000; 88:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/2\">",
"      Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/3\">",
"      Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007; 56:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/4\">",
"      Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases. Cancer 2008; 113:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/5\">",
"      Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004; 30:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/6\">",
"      Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995; 164:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/7\">",
"      Yagi Y, Ueda K, Maruyama S, Noborio R. Bednar tumor: a report of two cases. J Dermatol 2004; 31:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/8\">",
"      Marcus JR, Few JW, Senger C, Reynolds M. Dermatofibrosarcoma protuberans and the Bednar tumor: treatment in the pediatric population. J Pediatr Surg 1998; 33:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/9\">",
"      Elgart GW, Hanly A, Busso M, Spencer JM. Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy. J Am Acad Dermatol 1999; 40:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/10\">",
"      Lindner NJ, Scarborough MT, Powell GJ, et al. Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 1999; 25:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/11\">",
"      Thornton SL, Reid J, Papay FA, Vidimos AT. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol 2005; 53:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/12\">",
"      Pappo AS, Rao BN, Cain A, et al. Dermatofibrosarcoma protuberans: the pediatric experience at St. Jude Children's Research Hospital. Pediatr Hematol Oncol 1997; 14:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/13\">",
"      Love WE, Keiler SA, Tamburro JE, et al. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol 2009; 61:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/14\">",
"      McKee PH, Fletcher CD. Dermatofibrosarcoma protuberans presenting in infancy and childhood. J Cutan Pathol 1991; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/15\">",
"      Connelly JH, Evans HL. Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol 1992; 16:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/16\">",
"      Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/17\">",
"      Nishio J, Iwasaki H, Ishiguro M, et al. Supernumerary ring chromosome in a Bednar tumor (pigmented dermatofibrosarcoma protuberans) is composed of interspersed sequences from chromosomes 17 and 22: a fluorescence in situ hybridization and comparative genomic hybridization analysis. Genes Chromosomes Cancer 2001; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/18\">",
"      Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/19\">",
"      Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 2003; 140:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/20\">",
"      Sj&ouml;blom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61:5778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/21\">",
"      McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol 2006; 18:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/22\">",
"      Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, et al. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet 2001; 92:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/23\">",
"      Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008; 39:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/24\">",
"      Abbott JJ, Erickson-Johnson M, Wang X, et al. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol 2006; 19:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/25\">",
"      Wang J, Morimitsu Y, Okamoto S, et al. COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn 2000; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/26\">",
"      Takahira T, Oda Y, Tamiya S, et al. Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 2004; 35:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/27\">",
"      Haycox CL, Odland PB, Olbricht SM, Piepkorn M. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997; 37:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/28\">",
"      Reimann JD, Fletcher CD. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 2007; 31:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/29\">",
"      BEDNAR B. Storiform neurofibromas of the skin, pigmented and nonpigmented. Cancer 1957; 10:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/30\">",
"      Gayner SM, Lewis JE, McCaffrey TV. Effect of resection margins on dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol Head Neck Surg 1997; 123:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/31\">",
"      Stojadinovic A, Karpoff HM, Antonescu CR, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 2000; 7:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/32\">",
"      Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000; 24:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/33\">",
"      Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous (\"high-grade\") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/34\">",
"      Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 2006; 30:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/35\">",
"      Ding J, Hashimoto H, Enjoji M. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. A clinicopathologic study of nine cases and a comparison with allied tumors. Cancer 1989; 64:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/36\">",
"      Szollosi Z, Nemes Z. Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases. J Clin Pathol 2005; 58:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/37\">",
"      Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol 1988; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/38\">",
"      Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993; 15:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/39\">",
"      Kamino H, Reddy VB, Gero M, Greco MA. Dermatomyofibroma. A benign cutaneous, plaque-like proliferation of fibroblasts and myofibroblasts in young adults. J Cutan Pathol 1992; 19:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/40\">",
"      Zelger B, Sidoroff A, Stanzl U, et al. Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinicopathologic comparison. Am J Surg Pathol 1994; 18:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/41\">",
"      Sato N, Kimura K, Tomita Y. Recurrent dermatofibrosarcoma protuberans with myxoid and fibrosarcomatous changes paralleled by loss of CD34 expression. J Dermatol 1995; 22:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/42\">",
"      Calikoglu E, Augsburger E, Chavaz P, et al. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. J Cutan Pathol 2003; 30:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/43\">",
"      Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 2008; 26:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/44\">",
"      Allan AE, Tsou HC, Harrington A, et al. Clonal origin of dermatofibrosarcoma protuberans. J Invest Dermatol 1993; 100:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/45\">",
"      Dominguez-Malag&oacute;n HR, Ord&oacute;&ntilde;ez NG, Mackay B. Dermatofibrosarcoma protuberans: ultrastructural and immunocytochemical observations. Ultrastruct Pathol 1995; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/46\">",
"      Aiba S, Tabata N, Ishii H, et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol 1992; 127:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/47\">",
"      Nickoloff BJ. The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi's sarcoma. Arch Dermatol 1991; 127:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/48\">",
"      Tanaka A, Hatoko M, Tada H, et al. Dermatofibrosarcoma protuberans arising from a burn scar of the axilla. Ann Plast Surg 2004; 52:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/49\">",
"      Green JJ, Heymann WR. Dermatofibrosarcoma protuberans occurring in a smallpox vaccination scar. J Am Acad Dermatol 2003; 48:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/50\">",
"      Baker PA, O'Dowd GJ, Khan IU. Dermatofibrosarcoma protuberans arising in a decorative tattoo. Sarcoma 2005; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/51\">",
"      Bague S, Folpe AL. Dermatofibrosarcoma protuberans presenting as a subcutaneous mass: a clinicopathological study of 15 cases with exclusive or near-exclusive subcutaneous involvement. Am J Dermatopathol 2008; 30:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/52\">",
"      Lin JY, Sheen-Chen SM, Hsu W, et al. Dermatofibrosarcoma protuberans of the breast. Tumori 2008; 94:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/53\">",
"      Lee SJ, Mahoney MC, Shaughnessy E. Dermatofibrosarcoma protuberans of the breast: imaging features and review of the literature. AJR Am J Roentgenol 2009; 193:W64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/54\">",
"      Parlette LE, Smith CK, Germain LM, et al. Accelerated growth of dermatofibrosarcoma protuberans during pregnancy. J Am Acad Dermatol 1999; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/55\">",
"      Har-Shai Y, Govrin-Yehudain J, Ullmann Y, et al. Dermatofibrosarcoma protuberans appearing during pregnancy. Ann Plast Surg 1993; 31:91.",
"     </a>",
"    </li>",
"    <li>",
"     Enzinger FM, Weiss SW. Fibrohistiocytic tumors of intermediate malignancy. In: Soft Tissue Tumors, Stamatis G (Ed), Mosby, St. Louis 1988. p.252.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/57\">",
"      Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005; 23:7669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/58\">",
"      Domanski HA, Gustafson P. Cytologic features of primary, recurrent, and metastatic dermatofibrosarcoma protuberans. Cancer 2002; 96:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/59\">",
"      Klijanienko J, Caillaud JM, Lagac&eacute; R. Fine-needle aspiration of primary and recurrent dermatofibrosarcoma protuberans. Diagn Cytopathol 2004; 30:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/60\">",
"      Torreggiani WC, Al-Ismail K, Munk PL, et al. Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol 2002; 178:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/61\">",
"      Enneking WF, Spanier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 1980; 62:1027.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/63\">",
"      Ugurel S, Kortmann RD, Mohr P, et al. Short German guidelines: dermatofibrosarcoma protuberans. J Dtsch Dermatol Ges 2008; 6 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/64\">",
"      Mavili ME, Gursu KG, Gokoz A. Dermatofibrosarcoma with lymph node involvement. Ann Plast Surg 1994; 32:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/65\">",
"      Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996; 14:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/66\">",
"      Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/67\">",
"      Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003; 27:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/68\">",
"      Khatri VP, Galante JM, Bold RJ, et al. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 2003; 10:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/69\">",
"      Arnaud EJ, Perrault M, Revol M, et al. Surgical treatment of dermatofibrosarcoma protuberans. Plast Reconstr Surg 1997; 100:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/70\">",
"      Stojadinovic A, Hoos A, Karpoff HM, et al. Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatment. Arch Surg 2001; 136:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/71\">",
"      Behbahani R, Patenotre P, Capon N, et al. [To a margin reduction in the dermatofibrosarcoma protuberans? Retrospective study of 34 cases]. Ann Chir Plast Esthet 2005; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/72\">",
"      Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/73\">",
"      DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004; 100:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/74\">",
"      Popov P, B&ouml;hling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for dermatofibrosarcoma protuberans. Plast Reconstr Surg 2007; 119:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/75\">",
"      Foroozan M, Sei JF, Amini M, et al. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol 2012; 148:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/76\">",
"      Guill&eacute;n DR, Cockerell CJ. Cutaneous and subcutaneous sarcomas. Clin Dermatol 2001; 19:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/77\">",
"      D'Andrea F, Vozza A, Brongo S, et al. Dermatofibrosarcoma protuberans: experience with 14 cases. J Eur Acad Dermatol Venereol 2001; 15:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/78\">",
"      Kimmel Z, Ratner D, Kim JY, et al. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 2007; 14:2113.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/80\">",
"      Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010; 17:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/81\">",
"      Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004; 101:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/82\">",
"      Wacker J, Khan-Durani B, Hartschuh W. Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann Surg Oncol 2004; 11:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/83\">",
"      Nouri K, Lodha R, Jimenez G, Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg 2002; 28:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/84\">",
"      Robinson JK. Dermatofibrosarcoma protuberans resected by Mohs' surgery (chemosurgery). A 5-year prospective study. J Am Acad Dermatol 1985; 12:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/85\">",
"      Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997; 37:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/86\">",
"      Haycox CL, Odland PB, Olbricht SM, Casey B. Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Ann Plast Surg 1997; 38:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/87\">",
"      Nelson RA, Arlette JP. Mohs micrographic surgery and dermatofibrosarcoma protuberans: a multidisciplinary approach in 44 patients. Ann Plast Surg 2008; 60:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/88\">",
"      Lemm D, M&uuml;gge LO, Mentzel T, H&ouml;ffken K. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009; 135:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/89\">",
"      Ah-Weng A, Marsden JR, Sanders DS, Waters R. Dermatofibrosarcoma protuberans treated by micrographic surgery. Br J Cancer 2002; 87:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/90\">",
"      Massey RA, Tok J, Strippoli BA, et al. A comparison of frozen and paraffin sections in dermatofibrosarcoma protuberans. Dermatol Surg 1998; 24:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/91\">",
"      Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998; 40:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/92\">",
"      Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000; 57:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/93\">",
"      Haas RL, Keus RB, Loftus BM, et al. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer 1997; 33:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/94\">",
"      Dagan R, Morris CG, Zlotecki RA, et al. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005; 28:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/95\">",
"      Parsons JT, Zlotecki RA, Reddy KA, et al. The role of radiotherapy and limb-conserving surgery in the management of soft-tissue sarcomas in adults. Hematol Oncol Clin North Am 2001; 15:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/96\">",
"      Kabumoto T, Fujiwara H, Kariya N, et al. Skin metastasis of dermatofibrosarcoma protuberans with distinct morphological features, confirmed by COL1A1-PDGFB fusion gene analysis. J Am Acad Dermatol 2009; 61:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/97\">",
"      Monnier D, Vidal C, Martin L, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol 2006; 20:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/98\">",
"      Lal P, Sharma R, Mohan H, Sekhon MS. Dermatofibrosarcoma protuberans metastasizing to lymph nodes: a case report and review of literature. J Surg Oncol 1999; 72:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/99\">",
"      Westermann GW, Buerger H, Kappes U, et al. Dermatofibrosarcoma protuberans with lung metastasis in a patient with progressive systemic sclerosis. South Med J 2002; 95:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/100\">",
"      McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005; 23:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/101\">",
"      Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004; 151:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/102\">",
"      Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/103\">",
"      Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/104\">",
"      Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005; 16:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/105\">",
"      Lemm D, Muegge LO, Hoeffken K, et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Oral Maxillofac Surg 2008; 12:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/106\">",
"      Savoia P, Ortoncelli M, Quaglino P, Bernengo MG. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatol Surg 2006; 32:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/107\">",
"      Wright TI, Petersen JE. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007; 33:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/108\">",
"      Price VE, Fletcher JA, Zielenska M, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005; 44:511.",
"     </a>",
"    </li>",
"    <li>",
"     Misset J, Kerob D, Porcher R, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Results of a multicentric phase II study on 25 patients (abstract 10032). J Clin Oncol 2007; 27:552s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/110\">",
"      Han A, Chen EH, Niedt G, et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009; 145:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/111\">",
"      K&eacute;rob D, Porcher R, V&eacute;rola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010; 16:3288.",
"     </a>",
"    </li>",
"    <li>",
"     Neoadjuvant imatinib in DFSP, sponsored by the Sarcoma Alliance for Research through Collaboration. file://clinicaltrials.gov/ct2/show/NCT00243191?term=00243191&amp;rank=1 (Accessed on November 01, 2012).",
"    </li>",
"    <li>",
"     A short course of neoadjuvant Gleevec (imatinib mesylate) in DFSP (NCT 00176709). file://clinicaltrials.gov/ct2/results?term=00176709 (Accessed on November 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/50/13098/abstract/114\">",
"      Ng A, Nishikawa H, Lander A, Grundy R. Chemosensitivity in pediatric dermatofibrosarcoma protuberans. J Pediatr Hematol Oncol 2005; 27:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7747 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13098=[""].join("\n");
var outline_f12_50_13098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOLOGY AND HISTOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Molecular diagnostics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS AND STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Staging evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Staging systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Wide local excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mohs micrographic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - RT following surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF LOCALLY ADVANCED, RECURRENT, AND METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Neoadjuvant and adjuvant imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Other tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Conventional chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/37/6749\" title=\"table 1\">",
"      IHC dermal spindle cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/13/23773\" title=\"table 2\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/30/10733\" title=\"table 3\">",
"      2002 AJCC staging of STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/60/36812\" title=\"table 4\">",
"      DFSP outcomes RT conserv surg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_50_13099="Curth postulates";
var content_f12_50_13099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Curth's postulates*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Postulates",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definitions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Concurrent onset",
"       </td>",
"       <td>",
"        The dermatosis and malignancy occur concurrently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Parallel course",
"       </td>",
"       <td>",
"        If the malignancy is treated successfully or recurs, the dermatosis follows a similar course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Uniformity",
"       </td>",
"       <td>",
"        A specific malignancy is consistently associated with a specific dermatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Statistical significance",
"       </td>",
"       <td>",
"        There is a statistically significant association between the malignancy and the dermatosis based upon case-control studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Genetic basis",
"       </td>",
"       <td>",
"        There is a genetic association between the malignancy and dermatosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Curth's postulates are criteria used to identify a consistent relationship between an internal malignancy and a cutaneous disorder. All criteria do not have to be met.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin 2009; 59:73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13099=[""].join("\n");
var outline_f12_50_13099=null;
var title_f12_50_13100="Risks and benefits of enteral feeding tubes";
var content_f12_50_13100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risks and benefits of enteral feeding tubes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Timing of tube insertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Prophylactic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        More effective weight maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased need for additional hospitalization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Better quality of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Reactive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feeding tube avoided if unnecessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased risk of delayed dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Less prolonged use of enteral feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feeding tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nasogastric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Easier to insert",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased risk of serious complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower costs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potentially shorter duration of tube dependency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pharyngoesophageal dilatation less likely to be required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Percutaneous endoscopic gastrostomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        More comfortable than a nasogastric tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Less likely to be displaced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        More effective weight maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Improved quality of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unlimited duration of use possible",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adopted from Koyfman SA, Adelstein DJ. Enteral Feeding Tubes in Patients Undergoing Definitive Chemoradiation Therapy for Head-and-Neck Cancer: A&nbsp;Critical Review Int J. Radiat Oncol Bio Phys 2012: 84:581.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13100=[""].join("\n");
var outline_f12_50_13100=null;
var title_f12_50_13101="Soc and govt recs mamm scrn";
var content_f12_50_13101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Government/society recommendations for routine mammographic screening in women at average risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Group (date)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Frequency of screening (yr)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Initiation of screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        40-49 yr of age",
"       </td>",
"       <td class=\"subtitle2\">",
"        50-69 yr of age",
"       </td>",
"       <td class=\"subtitle2\">",
"        &ge;70 yr of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Government-sponsored groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        US Preventive Services Task Force (2009)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Individualize*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes, to age 75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Canadian Task Force on Preventive Health Care (2011)",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        Recommend against*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes, to age 74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        National Cancer Institute (2010)",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advisory Committee on Cancer Prevention in the EU",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        No",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        National Health Service, United Kingdom (2011)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Yes, start age 47",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes, to age 73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Medical societies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American College of Obstetricians and Gynecologists (2011)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American Medical Association (2002)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American College of Physicians (2007)",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        Individualize*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American Academy of Family Physicians (2009)",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        Individualize*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes, to age 74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American Cancer Society (2010)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American College of Radiology (2010)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Coalitions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        National Comprehensive Cancer Network (2011)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Women should be counseled about the risks and benefits of mammography; individualized decision based on risk and patient preference.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If done on women in their 40s, screening should be part of an organized program, done every 12 to 18 months, and include information about benefits and risks.",
"     <br/>",
"     &Delta; Discuss with doctor and individualize decision after age 75.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13101=[""].join("\n");
var outline_f12_50_13101=null;
var title_f12_50_13102="OCD related diseases";
var content_f12_50_13102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obsessive-compulsive-related disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 259px; background-image: url(data:image/gif;base64,R0lGODlhcQEDAdUAAP///4CAgEBAQMDAwAAz/wAAAKCgoICZ/0Bm//Dw8ODg4NDQ0DAwMFBQUMDN/wBmMyAgIGBgYLCwsHBwcJCQkICzmRBA/1Bz/6Cz/3CN/2CA/9DZ/yBN/zBZ/0CMZsDZzbDA/xAQEODm/5Cm//Dz/1CWcxBwQKDGs9Dj2TCDWWCggHCpjfD28yB5TbDQwODs5pC8pgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABxAQMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqJ0Oqw56GwgYYhkIRrNIr7FOthgIGwAIGanCTgTFBBa+cwgEQiIHrWEYB0IEtL/MRw4E007LAA4HIgDVw+VKxQAjBBcABxgb0yQHCBcgQhsawCRCDvkavv0Q/JMmhCA4Bxcu+BKRT58DDtscOGtFYtY/Ie5GCNyHj14ujCMATAQAIhxBDAQ4hFsGImEyfgQy5LMHoGOGfSTpQfwWbhyt/xHcDoQ0Vw6dNlrH0HWwcKADgQ0iLHQ4IPUbgakInl2dNw+btwPVqFr4llUDAQ0YLFTDoG3a0qYWxBXrAFGDiK0a2A25QIAESnZLrwHIcKzXMg5OORDRptIpVKlUO5DcuhNsK3JmN2w4S7ToNqexrt4La1YoAXuEN/AVJ3J1M2+CLQ8m0ApDPnKw224OBoJASHIkqm3mkGEEzoKnLzgNrkGwTyGwnS7eNtk06qeuv9J+ri1D6s7DiiGARc3a0QPowW23DBs6NvfwZVsmnOGo87ZtrU4j9xwEArWSDXEXYSiZZQ9s/MHWnn76yUebgszIxh8HFiAGXnjvlTeEBRawNf/CO+s8NJY6GoBjWono8XVBBmq14xsIHF4DAkq0sLRBfhUi9NRzPvUDggMxEuHUWMv05VxKEkE4XYmObXaBiC4eAEJl2/EHlm8XCoMOEfzVxFdK9mAAUQfJHACRBfaYeQwIG0CkXIQppeTLBmotQwuMvuW3QWK58FeNCE5d9ZIQ6rBTKHwuPqXkENqo1WFBY/pCwmFUXmbNXUZmqWkYsonSW3ObhupFp6HwBc0gq+xDgkRa4PIEME7wohl5Vbgq6q1hFMNOflnw2oQ7Tlg2UhW+4mrsFsasQh0AvCAQ0kgjuQMPABUJBNCyGtUjBAn5pNdOLgFdNIRq49E2UrVZEUr/D03SxpMPX/HMoy04G7CVzngZsFaIrMfmcVWFvU1DH18j5JdfUsy8tZQI+Q18GgBOyUQdOdpgxY1IHHal7DQUHpCBYg7bgzDEMZUGMVOOgaXWAWZl0NSpgOTWU793rFUNdRWiV43BEwe422QF4yxZcE9ydjAtrok0hDqxWIajBRr0VBXR4/hs9DablbUNWDSp+AwZLQnUCkPWMiulS+oCIwLZDkH0DDjiVCtuRhvV9O5H6mprtggj6DvYeBdJ40DdgtfN7HhDNTvvAfVK1NBNZrekED/++NLsUIrgVsx+KqHHFnVHwzQNfhNbszPopTtXhIMbe3nmXaYjZR7qWmWV/16n3AZKExh/HXBBOJDFeFhiALT88uAsn5XWWrIpHNc4V9V111R5ERHyNWrBrBKLii2jAWHseA/+bBkQDMCKajqT1DNaNzd8SlZZ7DDmiFC8+fkRSbMZU8vsZw0AOeLLjajDl5L4JjgccABh/JeOs5iIUSFaRutgMTjsnAYsv7EGCXK0QAB2yAEf6pQGCkYY+nlBHVOJBYk0Fh1meA0atrGTcyzzs95kkFrCSUlxjgPAoa3jGjzkxyxa1ELnSCdnYKGFMxAAEfXsLoaaE4J0khaVznWpftYwGbccJbCUmKxLe0pJLPJDAr5YIBjMqlPq2nGm3c1GKrTJz5c4EIsyHv8DjV1aXv+8VAwOGBAaVLkjGboSE7BEDT0iUFLuigEC+tgHNk6jHY/I4R8AcSl2qhtCb+ohHSUpKSXocUdUOmAb2nTKkVEUzIJA6blbsUVHbgTFCOrzl8104EcZeIVXmDFCBfqGJTSSETy2E8Ad+QkBPgLSWPZyQSwtCCPbmBIzJHgoav4QXg4QXARNuR0ZBVNJJDIRNgkiKrOAshTSXMc+QBCoDiRyl+1wVDDodLM7qQUo2wkjHTXkE0DNZVB2PCOiiECCxOzkMNXYB0IRoCoNcLF4x3CKeqBBTxkuSk1o2uIxLkazju7hmc/0qEhNAdIM3WoAKE0pGSawAC8sYAL/I40pGQIQAAEIgKZWGIAAhKBTJAhgAF7oqUyHGgacAmAADWgAUAEQAJ4CFaUGMAAAJCCABrQ0ABAIwACwqlWmCiACCWCqEKgqAAkUoaZWXYBUAaAACjCVqhEQQgLQulMFGGCrR03qUgNA1QkkIAI/HWtVWxqHlCqACSxtwkvPkNghKOCwiG3pAsIqhcWOAqcKgMBjNQuAAggBpwEIwQQMIIEGJCCzCTAAAwZg19UqYAJNpeoQFgCB065VCBRoAAAWIIEEhCCsAYBpAaTaAKnCFgAG2OkAQtCAAGR2s4cdLgCSqgDaTtW0qI1DAWjKALcqIbBMEGoZwCuEqDYhsI2N/4J4Q4FTCjSVqW71LFObatQGRICmEEDpTo+63xDQNADyZWsIKLDUIajWAISNgFQ5K1+c/pa/EAaAez8b38++17P2xW+B3SBfoSY3ApBFagPyq1YhtJUIc63qTikAWQT/9avA7euLl/rhw9oVr3wVAEwBIIDcNuCwKAXAi/1KBBHnF7mHRWtLFQDYtSKYwCluwH6palW23vW9lwDte3HaYPq+t8cpTYBQhVqAlG5YAQFgwH6HMIAJZHW3ECitELrcWZ4qd79G5bKF58xjAqOUsm8oM1LNagDTDgACbGWAAhKwWt8Cd8dCOG5yAXBcRzfArRJoqXSpa91CixnRy21uZ//Nemke+5UCccUpA6SaaccqmtFA/Wlud2vW/CaguDzOapubOunSnra2ocayJXC6AAYIQQAtffB95/tZ3QpZAQMw9lGl3WMhEJath01AgHcbVtnmeql0Xu1U72xtamt6z3UOgLNPq12aAna6S0U2BXYcWAUDgLNDeHBPM4vcuEagARKALJ3rrNRjL0C8Hd5pYHtK02IfYd7HjvUADizZ/SKVx0vV904zjFX9biLPDGDAeykAgap6eQgTULOieSwAqdrUALcOubMTLYBVE0ECKiesaodA52Lbl9yfDfmF0S3flNccsoEewmrB+1OjBpa2ciZCwoVQXAboPAIhAOrAPcv/dI/zGcIL3ylN1zsEp0v8qG7WqsUVDm479znMZCcqE+ydCfkmQLMQv/u4hSDubxdB3N4+tMUj3dStSximekd4pN0a9vn6NttI97a4fzrZvT84AIxfKuDFvm5or1nuTOC3JgpgU5v/NeRmpTQDItD3nRfB5+8WQpyDbtOwGv70DDArwmsOVoxDGKc4tynSVc96iQff6lMNee/BC/v9Gl3RcQe9sei+BNFvYdvSz74brL8E6msB+9pPQmoxP3wjWJYJn49C+pVw/vC7XwoiHwDJlRD9I4D/CfdHQv3fz3/9rzmsLFZek0VXglVldlVT3lUAcMVTUtZ7AyABgMVbX/VZ/0IGWL1HBDUVAQd3U9WWVwWHXAtAYF7VewsgZcI2B4YVB4v1WFDAgu/nWxMwAJRVab8laTvla6h1aDLIYMQlVQtwWKjmVdUVAj04BKXWaigXV7ylg3cHXc+Va1p1XLIVApPlXXWwXeomAIDGBj1lXktgVF74fmgmACEQV/xmAHGlcdN1Xx0nVIFFZwmQW2rGbHVGhwDwbwFXBA/mdhg3YfDlewDgXzTlWRAQg1s4BwE2aeNmgAZQU2tVgmVlZTg2WGzVZDwFgYHFZJTYUyiFZv+VVzDGcs4VZJroZKX1Y6B3ZFV3bmDnZzLohlq3Z90lZmI3dHbYb1kndUW2X023Zf9NBV6CFmRx2AB7SAfbBgG8hV3Ahox394Ov9lPBNmu8dW8yiGs1VV2IVl1w9nsBIGZtZmw/KGH+FgEyiFO2hms6FodxNVIHJ1ecJXh8B1SypW5y5XkRV4dcFlaTZlQDd1SERwQtZ22w6HA81lJM510tpXkbJgfb9lMcl19CRVMUcFM1pXbltWoVx4B0KF9oKACexXDvRVthNYxzmGcBsAAWp1uNN1IKMGI1l3r3lnrNF2kqZ4++R2cGUHLvxo/oxlRqpoVEgJI2JQGw6JMid49C1gAyN10hB2nGSAS1BWZ/FpHuZlji1Wa6tnYbSWkgVmcgKWR9N4tfOV9jxnYRJn3/3Bd+ARYBMEWPzyZUVndolLWB1tZtO3V5bsWTkagAH1mLd2iFBaCPYrdjDgZcmXeWoOd9all6WPZ80BYCNfdeqvWSQnV8LYVzqwdcQ0dbOtaXZEl6NoVcOllXarYAwKd8YbWS/beaR7B/rPmaheCasOkGZhZkinWIR2BeibWQs9mbXEBTNmVUSGBU6ZUEOBVY6+ebypkFRiViNBaCOnVTdnVYkOhWpbhngdVUkHiCpiBmYOCCy9kFmKVZTygAuhYB5JgAP5VZVUiNtyZVxxmLVBiHw0ABZfYFYRieW9BeW3aYdChrkIaSGhmfdVaIMjgMWbWOB9iB1wmCIpiBCTBX/yPZjUE2AUNZBAuKkFKWes7FV2t1Ys75WZSYXDcFelqGnXv1ZVuFZWXJbG8oZLlVjKZQbL7FU7bGWefocromhSumcHkZW0KGbza6g4/1jFp3U8uFWyBGnninW9N4oLhGVMRmboAYXBF3aNYWiIbporGokKkwAW4FcBFGeSkJiIIIYELAeuuIU21GhhsGixMJnIVnhAvWVv1JcSZWU28mpVsmdEipAKWZnWqmW5jZewSKYU0pDBCgZhAQV7DYosBoZmN1n/OFcwb5pry4VeTYiXXIXwJqkmiXVZllVsKpnx5FkDValHgJiB24ZPnFWf+FeH3Hh9BYW1l6jAFJkMhWef9UFW1pyp2meixgaoREmanJl5mAGHMMYFq5h1wMMFfdOKizOqZANZnNum3zF3RHaZl3OKjAGqzgGq7iOq6P4J1NwJvkmq5ZYJ/o+nU8pq7wugUJ6lQUOADbBZ8VGIo55leA1a5EUWDgaQXJ6QTrV3lLYLDvR6MhQHRsVWbndoSaRlw/Zl2hEmClWgX51wTgV5xIwLHaN6xiypOd6ll4KHAMW7Fl141YRqGYqHNfBVlUZlYKOIGVGJDIdYot9lUNhmbTSWkX6lVVZgCLZoG4OVSLap6pZosBxpFYF4tbWbH/VaLi5qs1lQALsLCehqU4Z1udVYQ5amrqeF2nJV+k51z/gWVWTSiNZuWQmHZtcoeqCwtxfDlnlPWR/2h4FZtSy4aGdwifKvqByCamPGdhAppXvtdTgku2Q7BwFpp1eIpxJfuxVghwd9eZQSdcPll7+GiLm2Kx70WFC/ufOhVvo6uLZKmVjQeM7vpTlnq4aed7aJiL8dovnvtZe4pTNZp3iBYA68iKhfmHjVdpihtxVgprvMp2S3Vcs3sstduwlIVVL1mBqCe9JUpnhZqaT7VT6nlTw4txjFZVq8WtTfeTRbu8/cK3PWm+6osFQnqx6/u+8Bu/8ju/ypmfoWK/9AsIBiBdorK/t5W/guC/98u/AEwIApwlB1zAhZDARMHACmzA/wRcDg78wBD8v6kwwRRcwcOAwRmswajAwR3swaUAwiEswqJAwiVswp+AwimswpzAwi3swpkAwzEsw5ZAwzVsw5OAwzmsw5DAwz3sw40AxEEsxIpAxEVsxIeAxEmsxE7cxEccwYvAxFC8wFKMCFRcxVZswYaQxVq8wFwMxl88xmRcxmZ8xmicxmq8xmzcxm78xnAcx3I8x2j8AhVQAScwBCvgAV2AAh6Qx3dwAh6AAkbgx4A8BYKMAoZsBYucxifwAC2QAg+QAiwAAB7wAF1gxx+ABxXwAJtcBJpcBZ38AaFcBR/wABWQxi8AyZUMAw+gApb8AC7gASpQySywxx6Qyv8AIMgeAANC4AIlQMubDMzCrMkoUAGb/AEVQMgfEMwrUMlFwAIw4AG9DAC3TMuEDAB4XAF/jAIlUAKVfALITMvhrMvirM2eDAAooAIeUAInoMksgMcAYMcuMM/srALZPATeTM2eHMrXnMtCMM0lUM/afALHbM3sXAKobM3cPNAAoMwocAKfHMSuvAJCwAIPYAKxrAIr8AAlAAAtYAIVsAItAAAdvQIKDQOPXAIVwNIr3dLIjMqr/NEK/QIu4NEd/dFFcMkrsAIanQIiDdQvAAAPMMkmAMmSDMuXzNEeHctCcMnoTMqTXAEqUAKnnMohDQCu/M4mkAIVYAIaPQQvANb/3OzJVw3SIk3SJv0AKC3LRH3UmCzJK6ACCw3UFSDJx5zRC13EnazLRI3JUA0AkgwAYK0CFTDUJtACd/wAvTzVeezKXp3HZ33JLGACfKzQd9wCmFzUjI0CrywEL+DZFn3TvszYUU3UfBzYgx3YUD3Knt0CKwADLHDWnQzMJiDNr1zWE73VUX3WhX3YhJ0C1tzUkywEng3LV+3ZuUzXi03QSXzTOu3Zws3amOzNmm0Cq6zYd5zHZc3W2nzJbH3Wj0zXeXzJd3zHD/0BH4ACZy0EZ33Wpj3KqO3UTk3dpz3LR50CZ73KdA3LnWzYdzzUQiDfo3zW1p3Rq8zH823aD73Q/1d9yrl8x8qczlAsyRXgApJcz5f8Aa780X/8AZfszaj8AeIMAytA4h5t4ihu1QuN0Rndyh79AS4Ay0UA1i6A4YTdAs38AIQc3+ls2hve4QCg0CXg05hc4CrgAh8A1u0tyeks3Uq+Avl8yla94ZMt0SGu0C7QyaWt4JWt4x2dymAt0Sot31DMAiqQ3wR9yUftAZWs0JCcx2h+1CLtAprt0Sxg50UNzu3d30NQAXeu00Qg4qaNApLcAoDs45sM5JDM2JWMAppdAoM9yi/g5CnA3nv9yCX9y5Yu4ELQ0V1t1gsN54huzQptAhY930JwAm2+0ITeAltO4XTsB4E967NZ6/+2nuu6vuu83uu+/uvA3sS2Geza577EzqfHXuzfmuwjZezM3uzL/uwd5ezSPu3RXu3HQu3Ynu3Xvu23ou3e/u3dHu6bAu7kXu7jfu4XYu7qvu7p3u5Ewe7wHu/vPu/DIO/2fu/1nu+ogO/83u/7/u+l4O8CP/ABX/CiQPAIn/AHv/CfoPAO//ANH/GcMOwUf/EYn/Eav/Ec3/Ee//EgH/KsyTCsoAWwUgv/MwWwYgtWwPIivzrGYFJVcEVDQE5UQA42TwUh9fJWYR5ncwHyQB7O0EgIYA/Q8jXAMQvpQhAlIQ7SsA+XYwTzYBa0QE5hUyIkcQHOwg+MYy/+cQE78Q3/Wg857WI3HoHx9uEicCQVasEwoOQYPMNAHfMxgoESIVEh5GM+QwA+SVT36+A7UrIO9KH20UQZzLBJ44Mw08MyekHxaS8htBBJ0xAwcf8cHBI14uANG0QmOGNFKY/3z+ENKAQsfLEPgcE1QpAdLrQ1OyEaNaFDxoH2VlIlkR9HtFP55KAarwMbZmEWctE5wDIExzRDRTIL8NQpnrQ16MEjOWFJFM83V9EKkO8iysIkT7E/XcFAFLQMuiQEvcEf48RRwBRFs5RN66AOgc8OnQIWUrITheIAINAc/JFMQRLxV4IO0x9JZ5ILhAEEHA3hACAgABcCgYMBIAgAKYfgBJA0/xaCpSgFbKhQJBQAohIuJEBGmwYcCA4pCcqhSg/nixEJEHWWOja8CAsNDxETFRcZGx0fISMlJykrLS8diC43OTs9P0FDRUdJSzczu0xVV1lbXV9hY2VnaWttb3FzdXd5e31/QRMMAigUOgVYFyYMExaAn6GjcxkCBiggOgtYB5ALlaXBw8VLub0SpCQEGpwpnAHaBwakAqQmBAQkpLQJEyIEJhIkCCAgwLkBEvwtSBdBigEJDRqcM2BMgQEA5RY0IAigIgCBBM9VHEhhnjp341CmRJkgxIQB5wA8TKAAQrMQAhsACEAPwL58CSAY2+eFgUUJCyLQC8BwoIIFISw2sP/4711OAfLKlQuxIAHJckl1MhwA4WVQCjkVqlS7NpqCgSEYNkgagCwAAwwYnNupT8oAeyHkDQWwgAGhEF4O7+05j95Vvo6zIoPg0iCyw1IOlwNw9a6Bk2xBh+ZFVgCFeC89FuCpWJsEBs4cC9bMly9rxpvlLYaMrFzXBjfLDdWmGfIECDxFJ1fuakFuoG5zejTGwHU+CssUaAuwLAGDwPxCGJvZIN+AnLZ1Npb3EAB5u7x5S/Fezr35i92uco3ZbXl//6IUaAACAairhwECFYhgmQUg4GrACbTpTh3vFiPEtXucukcAZ9Dbi8B7nBlLAH/uaw+vZTDSMET8Djrwtf//YIwxRsdkrNHGGzehEccdeezRxx+BDFLIIYms5LTTCFHAmEIMsKiRZuyyaILPOMmtyCuF3OkexRpykhAuD9HsGw+tPAbLM7PkyTPT4vHIH4C28yc3A0Y0hq5qOiLzIohyCyAdgOTkyJ91OBqmtHkENQnNRW1UTIDjBtirqJgWaIpBuyIayy7vFCiHTJqUDKqnqBpwChunBsNmrLKE4siZSxmN9T9H+wyAsC950qaB3DbUzFP1KFiNpH3QM8Cf4Vis0FgBBJPV2dBoZWy29B7jNZ5ufsVNsb2IzRWACSJolbjvwG312XNBizY9lsRzy9vrPFK1sBLJvHUzZ7p9LJ/s/0rETbd9m0VXYHHU3etCAdzlqx+88tlMAAOydSwAvLyldjEG/0FWithSzXjgj0EOWeSRSS7Z5JNRTlnllYM8DaZEvlFkykb0W2RmTm7ucrCXWe75EdXoorLfaQ/RUWahDTHaEqP3ytnnpxfxCeFBOYSUm5H64nNjeegMN+sGAjBmosE0IonOjfw1Z6AJLDJvxJAM9QwiYwiCSC96xvZzRCk+Yhvqp/cxoNRXsblrgE7Jeg5UUHETPAFNFWBAge7kuYomrrw6R6q068EbmQWMoUCsxI/riqGNzqI2tqik9Pxvn1UzzpllNe73qmDnIemqXTdeAF5/b1/GC7ceVc+wyv88OutA27FChkbtjM/3pn5fX7mANr/1uvZxt1WPxquiBR85mvLR04t9ymGAgsfh27rE51X/jlr0+as+ZcHw4Wi4ece1d0Pc4AWU/cincvHAxmAGMC+wGI1C6eiJRNrnr3I4hj16ylcD62e/kwkGYxDa2MPGpROKbW1hBfoWAyJQF4kdKCcRYKHxvEAYiCDDAAMiUQgneKD/WfA2MtSIBoHICZiIihIwMZYpjMiQIC6REgOaVCVqeA+eiSKKApgiE7GYRS1ukYtLtNLhNkOLMnWRjJEIXF4qtAiimamMbYSENu4CE6kRSiQP0wmk3uO1OsqtVHt620UQQiN6JEhRbjT/pCEK8JSXtSYiNHlcg4CyAMNVJFOqIl1BRDeY0DEFYbDSBqpgdUhR9gQC0eGLXHZCFs3sRDO8uxcOkeGb5aEncMca5SgLkCAl6oZNL1llNZKFG1gCQH3ss9g+tFGuNN7SjRF6onaiMxPNvCaBUgigqpIVHAgeU1/6Y+Yh99Edi+xjAi7qVAgIxJN7GKCE5ckmDW2IDFp2zIPftGeYMnhPfcZijfv05z8BGlCBokkYxFiSN4Q3EC/tDBFjPISSLOE0QzQJElAaaJGoYY0DFqIcgvMIISTqhXxOdKGSUFohwMSImF1USLOBSToINUGCHNQudlrIbbCnJt8hiZBO4kmb/zKCNpEGwG4liYBewOUYQhKqGA0BnUU+UpCLDICiLK0RSyiDjkbW5CsRQI1IA8O6i0CPNsWLFD0StznpYa4QqMvJBOjhQEudinAAiABJABCeryiFKS0pqVX/Qzy4tGcuqpSn5+zIMW6iR5C2wlZO8jWZr4KVLyHYSQDIqixbXuqIWkGMxQC7I9L00pgp9Ve+FsPYWvkKGfnyzfQou5jrIck2ytzH7pqXxsyGNkbN4VtQiMq3Th02afKzDbz4lba9TI8YeT0HWHJDIcqy51CD4Wb+kkunA9KnPOdBDm8DKyACNaycCMpWW43rLaB4TLlxxctR3zEgsJmIAcITqQ6dkUeABuDFu3zp4FCg0pfPqQi04B1YAgJmYAUnIoXfXfCDIRxhCU+YwhW28IUxnGENb5jDHfbwh0EcYhGPmMQlNvGJUZxiFXM4CAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hollander, E, Kwon, JH, Stein, DJ, et al, J Clin Psychiatry 1996; 57 (Suppl 8):3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13102=[""].join("\n");
var outline_f12_50_13102=null;
var title_f12_50_13103="Retinoscope";
var content_f12_50_13103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retinoscope is used to get an objective measure of refractive error that is not dependent upon patient response.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_50_13103=[""].join("\n");
var outline_f12_50_13103=null;
